Aliases & Classifications for Glioblastoma Multiforme

About this section

Aliases & Descriptions for Glioblastoma Multiforme:

Name: Glioblastoma Multiforme 11 13 48 66
Glioblastoma 37 66
Primary Glioblastoma Multiforme 11
Grade Iv Adult Astrocytic Tumor 11
Adult Glioblastoma Multiforme 11
 
Spongioblastoma Multiforme 11
Primary Glioblastoma 66
Adult Glioblastoma 66
Gbm 11

Classifications:



External Ids:

Disease Ontology11 DOID:3068
MeSH37 D005909

Summaries for Glioblastoma Multiforme

About this section
Disease Ontology:11 An astrocytoma characterized by the presence of small areas of necrotizing tissue that is surrounded by anaplastic cells as well as the presence of hyperplastic blood vessels, and that has material basis in abnormally proliferating cells derived from multiple cell types including astrocytes and oligondroctyes.

MalaCards based summary: Glioblastoma Multiforme, also known as glioblastoma, is related to pleomorphic xanthoastrocytoma and herpes simplex, and has symptoms including headache, seizures and headache. An important gene associated with Glioblastoma Multiforme is PTEN (Phosphatase And Tensin Homolog), and among its related pathways are TP53 network and TSH signaling pathway. The drug carmustine has been mentioned in the context of this disorder. Affiliated tissues include brain, t cells and endothelial, and related mouse phenotypes are respiratory system and craniofacial.

Wikipedia:69 Glioblastoma multiforme (GBM), also known as glioblastoma and grade IV astrocytoma, is the most common... more...

Related Diseases for Glioblastoma Multiforme

About this section

Diseases related to Glioblastoma Multiforme via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 262)
idRelated DiseaseScoreTop Affiliating Genes
1pleomorphic xanthoastrocytoma31.3IDH1, TP53
2herpes simplex31.1CDKN2A, EGFR, TP53
3spinal cord glioma31.0IDH1, MDM2, TP53
4medulloblastoma30.9DMBT1, MGMT, MYC, PDGFRA, TP53
5giant cell glioblastoma30.6AKT1, CDK4, CDKN2A, DMBT1, EGFR, IDH1
6neuroblastoma30.0AKT1, GSK3B, MDM2, MYC, TP53
7breast cancer28.7AKT1, CDK2, CDK4, EGF, EGFR, GPNMB
8prostate cancer28.1AKT1, AKT3, CDK2, CDK4, EGF, EGFR
9gliosarcoma27.2AKT1, AKT3, CDK2, CDK4, CDK6, CDKN2A
10brain glioblastoma multiforme12.4
11adult spinal cord glioblastoma multiforme12.2
12glioblastoma11.9
13goodpasture syndrome11.6
14glioma susceptibility 111.5
15peptic ulcer disease11.0EGFR, TP53
16malignant gastric teratoma11.0CDKN2A, MTOR
17salivary gland adenoid cystic carcinoma10.9CDKN2A, TP53
18cervical benign neoplasm10.9EGFR, MGMT, TP53
19intrahepatic bile duct cystadenoma10.9IDH1, MGMT, TP53
20papillary adenofibroma10.9MTOR, PDGFRA, TP53
21stampe sorensen syndrome10.9EGFR, MDM2, TP53
22cervical adenoid cystic carcinoma10.9IDH1, MGMT, TP53
23biliary papillomatosis10.9CDKN2A, TP53
24chromosome 7p duplication10.9CDK4, MDM2, TP53
25karak syndrome10.9CDK4, CDKN2A, PTEN
26esophagus verrucous carcinoma10.9CDKN2A, PTEN, TP53
27epithelioid leiomyosarcoma10.9MDM2, PDGFRA, PTEN
28myoepithelial carcinoma10.9EGFR, PDGFRA, TP53
29oral lichen planus10.9EGFR, MGMT, TP53
30malignant giant cell tumor of soft parts10.9CDKN2A, EGFR, PDGFRA
31central centrifugal cicatricial alopecia10.9CDKN2A, EGFR, MGMT
32anal squamous cell carcinoma10.9CDKN2A, EGFR, TP53
33non-congenital cyst of kidney10.9CDKN2A, EGFR, PTEN
34compartment syndrome10.9CDKN2A, PTEN, TP53
35pancreatic agenesis10.9CDKN2A, PDGFRA, TP53
36actinic keratosis10.9CDKN2A, EGFR, TP53
37ductal carcinoma in situ10.9CDKN2A, EGFR, TP53
38adenofibroma10.9CDK4, CDKN2A, TP53
39pelvic muscle wasting10.8CDKN2A, PTEN, TP53
40breast capillary hemangioma10.8CDK4, IDH1, MDM2
41cell type cancer10.8PDGFRA, PTEN, TP53
42emerinopathy10.8CDK4, MDM2, TP53
43preeclampsia/eclampsia 310.8CDKN2A, PDGFRA, TP53
44fallopian tube mucinous adenocarcinoma10.8CDKN2A, EGFR, TP53
45uterine corpus epithelioid leiomyosarcoma10.8EGFR, IDH1, PTEN, TP53
46progesterone-receptor positive breast cancer10.8EGFR, MTOR, TP53
47bladder verrucous squamous cell carcinoma10.8CDKN2A, MDM2, TP53
48epidural spinal canal angiolipoma10.8CDK4, CDKN2A, MDM2
49melanotic medulloblastoma10.8IDH1, MDM2, PTEN
50milker's nodule10.8CDKN2A, EGFR, TP53

Graphical network of the top 20 diseases related to Glioblastoma Multiforme:



Diseases related to glioblastoma multiforme

Symptoms for Glioblastoma Multiforme

About this section

UMLS symptoms related to Glioblastoma Multiforme:


headache, seizures

Drugs & Therapeutics for Glioblastoma Multiforme

About this section

FDA approved drugs:

id Drug Name Active Ingredient(s)16 Company Approval Date
1
Avastin16 42 BEVACIZUMAB Genentech July 2009
FDA Label: Avastin
Disease/s that Drug Treats:renal cell carcinoma & Colorectal Cancer
Indications and Usage:16 Avastin is a vascular endothelial growth factor-specific angiogenesisinhibitor indicated for the treatment of: Metastatic colorectal cancer, with intravenous 5-fluorouracil-basedchemotherapy for first- or second-line treatment. (1.1) Metastatic colorectal cancer, with fluoropyrimidine- irinotecan- orfluoropyrimidine-oxaliplatin-based chemotherapy for second-linetreatment in patients who have progressed on a first-line Avastincontainingregimen. (1.1) Non-squamous non-small cell lung cancer, with carboplatin and paclitaxelfor first line treatment of unresectable, locally advanced, recurrent ormetastatic disease. (1.2) Glioblastoma, as a single agent for adult patients with progressive diseasefollowing prior therapy. (1.3)-Effectiveness based on improvement in objective response rate. No dataavailable demonstrating improvement in disease-related symptoms orsurvival with Avastin. Metastatic renal cell carcinoma with interferon alfa (1.4) Cervical cancer, in combination with paclitaxel and cisplatin or paclitaxeland topotecan in persistent, recurrent, or metastatic disease. (1.5) Platinum-resistant recurrent epithelial ovarian, fallopian tube or primaryperitoneal cancer, in combination with paclitaxel, pegylated liposomaldoxorubicin or topotecan (1.6) Limitation of Use: Avastin is not indicated for adjuvant treatment of coloncancer. (1.1)
DrugBank Targets:14 1. Vascular endothelial growth factor A;2. Low affinity immunoglobulin gamma Fc region receptor III-B;3. Complement C1r subcomponent;4. Complement C1q subcomponent subunit A;5. Complement C1q subcomponent subunit B;6. Complement C1q subcomponent subunit C;7. Low affinity immunoglobulin gamma Fc region receptor III-A;8. High affinity immunoglobulin gamma Fc receptor I;9. Low affinity immunoglobulin gamma Fc region receptor II-a;10. Low affinity immunoglobulin gamma Fc region receptor II-b;11. Low affinity immunoglobulin gamma Fc region receptor II-c
Mechanism of Action:16 
Target: VEGF
Action: inhibitor
FDA: Bevacizumab binds VEGF and prevents the interaction of VEGF to its receptors (Flt-1 and KDR)697 on the surface of endothelial cells. The interaction of VEGF with its receptors leads to endothelial698 cell proliferation and new blood vessel formation in in vitro models of angiogenesis. Administration699 of bevacizumab to xenotransplant models of colon cancer in nude (athymic) mice caused reduction700 of microvascular growth and inhibition of metastatic disease progression
2
Gliadel Wafer16 42 CARMUSTINE Rhone-Poulenc Rorer, Guilford Pharmaceuticals February 1997
FDA Label: Gliadel Wafer
Disease/s that Drug Treats:brain cancer
Indications and Usage:16 GLIADELWaferisanalkylatingdrugindicatedforthetreatmentof: newly-diagnosedhigh-grade-malignantgliomaasanadjuncttosurgeryandradiation(1)and recurrentglioblastomamultiformeasanadjuncttosurgery(1)
DrugBank Targets:14 1. Glutathione reductase, mitochondrial;2. DNA;3. RNA
Mechanism of Action:16 
Target: DNA and RNA
Action: alkylating agent
FDA: The activity of GLIADEL Wafer is due to release of cytotoxic concentrations of carmustine, aDNA and RNA alkylating agent, into the tumor resection cavity. On exposure to the aqueousenvironment of the resection cavity, the anhydride bonds in the copolymer are hydrolyzed,releasing carmustine, carboxyphenoxypropane, and sebacic acid into the surrounding braintissue.
3
Temodar16 42 TEMOZOLOMIDE Schering-Plough August 1999
FDA Label: Temodar
Disease/s that Drug Treats:refractory anaplastic astrocytoma
Indications and Usage:16 TEMODAR is an alkylating drug indicated for the treatment of adultpatients with: Newly diagnosed glioblastoma multiforme (GBM) concomitantlywith radiotherapy and then as maintenance treatment. (1.1) Refractory anaplastic astrocytoma patients who have experienceddisease progression on a drug regimen containing nitrosoureaand procarbazine. (1.2)
DrugBank Targets:14 1. DNA
Mechanism of Action:16 
Target: DNA
Action: alkylizer
FDA: Temozolomide is not directly active but undergoes rapid nonenzymatic conversion at physiologic pH to the reactive compound5-(3-methyltriazen-1-yl)-imidazole-4-carboxamide (MTIC). The cytotoxicity of MTIC is thought to be primarily due to alkylation ofDNA. Alkylation (methylation) occurs mainly at the O6 and N7 positions of guanine.

Drugs for Glioblastoma Multiforme (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 290)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
BenzocainePhase 4, Phase 3, Phase 217941994-09-7, 94-09-72337
Synonyms:
(p-(Ethoxycarbonyl)phenylamine
06952_FLUKA
112909_ALDRICH
112909_SIAL
1333-08-0
23239-88-5
23239-88-5 (hydrochloride)
4 Aminobenzoic Acid Ethyl Ester
4-(Ethoxycarbonyl)aniline
4-(Ethoxycarbonyl)phenylamine
4-14-00-01129 (Beilstein Handbook Reference)
4-Aminobenzoate
4-Aminobenzoic acid
4-Aminobenzoic acid ethyl ester
4-Aminobenzoic acid, ethyl ester
4-Carbethoxyaniline
4-amino-benzoic acid ethyl ester
4-aminobenzoic acid ethyl ester
71123-91-6
94-09-7
94-09-7 (Parent)
A0271
AB00051923
AC1L1DGC
AC1Q341A
AC1Q64JE
AE-562/40377256
AI3-02081
AKOS000119763
AR-1H9065
Acetate, Benzocaine
Aethoform
Aethylium paraminobenzoicum
Amben ethyl ester
Americaine
Anaesthan-syngala
Anaesthesin
Anaesthesinum
Anaesthin
Anestezin
Anestezin [Russian]
Anesthesin
Anesthesine
Anesthone
BB_SC-0019
BPBio1_001017
BRD-K75466013-001-05-2
BRN 0638434
BSPBio_000923
BSPBio_001908
Baby Anbesol
Bensokain
Benzoak
Benzocaina
Benzocaina [INN-Spanish]
Benzocaine
Benzocaine (USP/INN)
Benzocaine Acetate
Benzocaine Formate
Benzocaine Hydrobromide
Benzocaine Hydrochloride
Benzocaine Methanesulfonate
Benzocaine [INN:BAN]
Benzocainum
Benzocainum [INN-Latin]
Benzoic acid, 4-amino-, ethyl ester
Benzoic acid, 4-amino-, ethyl ester, hydrochloride
Benzoic acid, amino-, ethyl ester
Benzoic acid, p-amino-, ethyl ester
C07527
CAS-94-09-7
CHEBI:116735
CHEMBL278172
CID2337
Caswell No. 430A
Chloraseptic
D001566
D00552
DB01086
Dermoplast
Diet Ayds
DivK1c_000932
E1501_SIGMA
EINECS 202-303-5
EPA Pesticide Chemical Code 097001
ETHYL-P-AMINOBENZOATE
Ethoform
Ethoforme
Ethyl 4-aminobenzoate
Ethyl 4-aminobenzoate hydrochloride
Ethyl 4-aminobenzoic acid
Ethyl Aminobenzoate
Ethyl PABA
 
Ethyl aminobenzoate
Ethyl aminobenzoate (JP15)
Ethyl aminobenzoate (VAN)
Ethyl aminobenzoic acid
Ethyl p-Aminobenzoate
Ethyl p-Aminophenylcarboxylate
Ethyl p-aminobenzenecarboxylate
Ethyl p-aminobenzoate
Ethyl p-aminobenzoic acid
Ethyl p-aminophenylcarboxylate
Ethylester kyseliny p-aminobenzoove
Ethylester kyseliny p-aminobenzoove [Czech]
Ethylis aminobenzoas
Formate, Benzocaine
HMS1570O05
HMS1920G09
HMS2091M11
HMS502O14
HSDB 7225
Hurricaine
Hydrobromide, Benzocaine
Hydrochloride, Benzocaine
I05-0204
IDI1_000932
Identhesin
KBio1_000932
KBio2_000474
KBio2_003042
KBio2_005610
KBio3_001408
KBioGR_000658
KBioSS_000474
Keloform
LS-35847
MLS001331704
MLS002153970
Methanesulfonate, Benzocaine
MolPort-000-871-526
NCGC00016352-01
NCGC00094598-01
NCGC00094598-02
NINDS_000932
NSC 122792
NSC 41531
NSC41531
NSC4688
Norcain
Norcaine
Norcainum
Oprea1_750694
Oprea1_827402
Ora-jel
Orabase-B
Orthesin
Otocain
Outgro
Parathesin
Parathesin (TN)
Parathesine
Prestwick0_000712
Prestwick1_000712
Prestwick2_000712
Prestwick3_000712
Prestwick_991
SMR000059025
SPBio_000134
SPBio_002844
SPECTRUM1500139
STK043620
Slim Mint Gum
Solarcaine
Solu H
Spectrum2_000117
Spectrum3_000314
Spectrum4_000249
Spectrum5_000860
Spectrum_000074
Topcaine
UNII-U3RSY48JW5
WLN: ZR DVO2
ZINC12358719
benzocaine
ethylaminobenzoate-4
h-4-abz-oet
nchembio.182-comp4
p-(Ethoxycarbonyl)aniline
p-Aminobenzoate
p-Aminobenzoic acid
p-Aminobenzoic acid ethyl ester
p-Aminobenzoic acid, ethyl ester
p-Aminobenzoic ethyl ester
p-Carbethoxyaniline
p-Ethoxycarboxylic Aniline
p-Ethoxycarboxylic aniline
2
TemozolomidePhase 4, Phase 3, Phase 2, Phase 1, Phase 067985622-93-15394
Synonyms:
3,4-Dihydro-3-methyl-4-oxoimidazo(5,1-d)-1,2,3,5-tetrazine-8-carboxamide
3,4-Dihydro-3-methyl-4-oxoimidazo(5,1-d)-as-tetrazine-8-carboxamide
3,4-dihydro-3-Methyl-4-oxoimidazo(5,1-D)-1,2,3,5-tetrazine-8-carboxamide
3,4-dihydro-3-Methyl-4-oxoimidazo(5,1-D)-as-tetrazine-8-carboxamide
3-Methyl-4-oxo-3,4-dihydroimidazo(5,1-D)(1,2,3,5)tetrazine-8-carboxamide
3-Methyl-4-oxo-3,4-dihydroimidazo(5,1-d)(1,2,3,5)tetrazine-8-carboxamide
3-Methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetraazine-8-carboxamide
3-methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide
3-methyl-4-oxoimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide
8-Carbamoyl-3-methylimidazo(5,1-D)-1,2,3,5-tetrazin-4(3H)-one
8-Carbamoyl-3-methylimidazo(5,1-d)-1,2,3,5-tetrazin-4(3H)-one
85622-93-1
AC-758
AC1L1K9B
BIDD:GT0204
BRN 5547136
Bio-0147
C047246
C6H6N6O2
CCRG 81045
CCRG-81045
CCRIS 8996
CHEBI:153686
CHEMBL810
CID5394
CPD000466338
D06067
DB00853
Essex brand of temozolomide
HMS2051O12
HMS2090B08
I06-0149
I14-1943
LS-80558
M B 39831
M & B 39831
M&B 39831
M&B-39831
 
M-39831
MB 39831
MLS000759447
MLS001424028
MLS002701861
Methazolastone
NCGC00167429-01
NCGC00167429-02
NCI60_003316
NSC 362856
NSC-362856
NSC362856
SAM001246636
SMR000466338
STK623541
Sch 52365
Sch-52365
Schering brand of temozolomide
Schering-Plough brand of temozolomide
TL8005593
TMZ
TMZ-Bioshuttle
Temodal
Temodal (TN)
Temodar
Temozolamide
Temozolodida
Temozolodida [Spanish]
Temozolomid
Temozolomida
Temozolomide (JAN/USAN/INN)
Temozolomide [INN:BAN]
Temozolomidum
Temozolomidum [Latin]
Témozolomide
UNII-YF1K15M17Y
ZINC01482184
m & b 39831
temozolomide
3
DacarbazinePhase 4, Phase 3, Phase 2, Phase 1, Phase 06514342-03-45351166
Synonyms:
(5E)-5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide
(5Z)-5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide
(Dimethyltriazeno)imidazolecarboxamide
37626-23-6
4(5)-(3,3-Dimethyl-1-triazeno)imidazole-4-carboxamide
4(5)-(3,3-Dimethyl-1-triazeno)imidazole-5(4)-carboxamide
4-(3,3-Dimethyl-1-triazeno)imidazole-5-carboxamide
4-(3,3-Dimethyltriazeno)imidazole-5-carboxamide
4-(5)-(3,3-Dimethyl-1-triazeno)imidazole-5(4)-carboxamide
4-(Dimethyltriazeno)imidazole-5-c arboxamide
4-(Dimethyltriazeno)imidazole-5-carboxamide
4-(or 5)-(3,3-Dimethyl-1-triazeno)imidazole-5(or 4)-carboxamide
4-(or 5)-(3,3-Dimethyl-1-triazeno)imidazole-5(or 4)-carboxamide
4-[(1E)-3,3-Dimethyltriaz-1-en-1-yl]-1H-imidazole-5-carboxamide
4-[3,3-dimethyltriaz-1-en-1-yl]-1H-imidazole-5-carboxamide
4342-03-4
5(or 4)-(dimethyltriazeno)imidazol e-4(or 5)-carboxamide
5(or 4)-(dimethyltriazeno)imidazole-4(or 5)-carboxamide
5-(3,3-Dimethyl-1-triazeno)imidazole-4-carboxamide
5-(3,3-Dimethyl-1-triazenyl)-1H-imidazole-4-carboxamide
5-(3,3-Dimethyl-1-triazenyl)imidazole-4-carboxamide
5-(3,3-Dimethyltri azeno)imidazole-4-carboxamide
5-(3,3-Dimethyltriazeno)-imidazole-4-carbamide
5-(3,3-Dimethyltriazeno)imidazole-4-carboxamide
5-(3,3-dimethyltriaz-1-en-1-yl)-1H-imidazole-4-carboxamide
5-(Dimethyltriazeno)-4-imidazolecarboxamide
5-(Dimethyltriazeno)imidazole-4-carboxamide
5-(Dimethyltriazeno)imidazole-4-carboximide
5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide
5-[3,3-Dimethyl-1-triazenyl]imidazole-4-carboxamide
94361-71-4
AC1NQXVV
AC1NS01W
AC1NS4BN
AI3-52825
BPBio1_000428
BRD-K35520305-001-07-8
BSPBio_000388
BSPBio_002091
Biocarbazin
Biocarbazine
Biocarbazine R
C6H10N6O
CAS-891986
CCRIS 190
CHEBI:4305
CHEMBL476
CID5281007
CID5351166
CID5353562
Carboxamide, Dimethyl Imidazole
D00288
D003606
D2390_SIGMA
D3634
DB00851
DIC
DTCI
DTIC
DTIC Dome
DTIC, DTIC-Dome, Dacarbazine
DTIC-Dome
DTICDome
DTIE
Dacarbazin
Dacarbazina
Dacarbazine
Dacarbazine (JAN/USP/INN)
Dacarbazine [USAN:INN:BAN:JAN]
Dacarbazino
Dacarbazino [INN-Spanish]
Dacarbazinum
Dacarbazinum [INN-Latin]
 
Dacatic
Decarbazine
Deticene
Di-me-triazenoimidazolecarboxamide
Di-methyl-triazenoimidazolecarboxamide
Dimethyl Imidazole Carboxamide
Dimethyl Triazeno Imidazole Carboxamide
Dimethyltriazenoimidazolecarboxamide
DivK1c_000326
Dtic-Dome
Dtic-Dome (TN)
Dtic-dome (tn)
EINECS 224-396-1
HE1150000
HMS1569D10
HMS2090A20
HMS2091I20
HMS501A08
HSDB 3219
I06-2280
I14-1659
ICDMT
ICDT
IDI1_000326
Imidazole Carboxamide
Imidazole Carboxamide, Dimethyl
Imidazole carboxamide
KBio1_000326
KBio2_001364
KBio2_003932
KBio2_006500
KBio3_001311
KBioGR_000896
KBioSS_001364
LS-119
MLS001332543
MLS001332544
MolPort-003-666-153
MolPort-003-846-120
MolPort-006-709-420
NCGC00016986-01
NCGC00091861-01
NCGC00091861-02
NCGC00091861-03
NCGC00091861-04
NCI-C04717
NCI60_004053
NCIMech_000261
NINDS_000326
NIOSH/HE1150000
NPFAPI-05
NSC 45388
NSC-45388
NSC45388
Prestwick0_000574
Prestwick1_000574
Prestwick2_000574
Prestwick3_000574
Prestwick_904
S1221_Selleck
SMP2_000251
SMR000857131
SPBio_001075
SPBio_002607
SPECTRUM1500218
ST51014976
Spectrum2_001148
Spectrum3_000366
Spectrum4_000308
Spectrum5_000823
Spectrum_000884
UNII-7GR28W0FJI
WLN: T5M CNJ DVZ ENUNN1&1
dacarbazine
4Alkylating AgentsPhase 4, Phase 3, Phase 2, Phase 1, Phase 04573
5tannic acidNutraceuticalPhase 4, Phase 3, Phase 21794
6
MiconazolePhase 2, Phase 3, Phase 1357322916-47-84189
Synonyms:
(+-)-1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl) imidazole
1-[2,4-Dichloro- beta-([2,4-dichloro- benzyl]oxy)phenethyl]imidazole
1-[2-(2,4-Dichloro-benzyloxy)-2-(2,4-dichloro-phenyl)-ethyl]-1H-imidazole
1-[2-(2,4-Dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]-1H-imidazole
1-[2-(2,4-dichlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole
1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole
1-[2-(2,4-dichlorophenyl)-2-{[(2,4-dichlorophenyl)methyl]oxy}ethyl]-1H-imidazole
1-{2-[(2,4-dichlorobenzyl)oxy]-2-(2,4-dichlorophenyl)ethyl}-1H-imidazole
22832-87-7 (NITRATE)
22916-47-8
75319-47-0
AB00053500
AC1L1HM1
AKOS001574474
Aflorix(nitrate)
Albistat(nitrate)
Andergin(nitrate)
BPBio1_000279
BRD-A82396632-001-03-0
BRD-A82396632-008-02-7
BRN 0965511
BSPBio_000253
BSPBio_002033
CCRIS 7924
CHEBI:6923
CHEMBL91
CID4189
CPD-4501
Conofite(nitrate)
D00416
DB01110
Dactarin
Daktarin IV
Daktarin iv
DivK1c_000156
EINECS 245-324-5
Epi-Monistat(nitrate)
Femizol-M
Florid(nitrate)
Gyno-Daktar(nitrate)
HMS1568M15
HMS2090B21
I14-14342
IDI1_000156
Imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl)methoxy)ethyl)- (9CI)
KBio1_000156
KBio2_001445
KBio2_004013
KBio2_006581
KBio3_001533
KBioGR_000581
KBioSS_001445
LS-78378
Lotrimin AF(nitrate)
MCZ
MJR 1762
MLS002222203
Micantin (nitrate)
Miconasil Nitrate
 
Miconazol
Miconazol [INN-Spanish]
Miconazole
Miconazole (JP15/USP/INN)
Miconazole 3
Miconazole 3 Combination Pack
Miconazole 7 Combination Pack
Miconazole [USAN:BAN:INN:JAN]
Miconazole nitrate salt
Miconazole-7
Miconazolo
Miconazolo [DCIT]
Miconazolum
Miconazolum [INN-Latin]
Micozole
Minostate
MolPort-002-557-553
Monazole 7
Monista (nitrate)
Monistat
Monistat (TN)
Monistat 1 Combination Pack
Monistat 3 Dual-Pak
Monistat 3 Vaginal Ovules
Monistat 5 Tampon
Monistat 7 Dual-Pak
Monistat 7 Vaginal Suppositories
Monistat Dual- PAK
Monistat IV
Monistat iv (TN)
Monistat iv (tn)
Monistat-Derm
NCI60_001353
NCI60_001380
NINDS_000156
NSC 170986
NSC169434
NSC170986
Novo-Miconazole Vaginal Ovules
Oprea1_091955
Prestwick0_000067
Prestwick1_000067
Prestwick2_000067
Prestwick3_000067
Prestwick_335
R 18134
R-14,889
SMR001307249
SPBio_000976
SPBio_002174
STK834405
STOCK1S-93556
Spectrum2_001048
Spectrum3_000507
Spectrum4_000061
Spectrum5_001297
Spectrum_000965
UNII-7NNO0D7S5M
Vusion
Zimycan
imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl) methoxy)ethyl)- (9CI)
miconazole
7interferonsPhase 3, Phase 2, Phase 1, Phase 02112
8
IsotretinoinPhase 3, Phase 2, Phase 11174759-48-25538, 5282379
Synonyms:
(13-cis)-Retinoate
(13-cis)-Retinoic acid
(13cis)-retinoic acid
(2Z,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenoic acid
(2Z,4E6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraenoic acid
(7E,9E,11E,13Z)-retinoic acid
(7e,9e,11e,13Z)-Retinoic acid
13 Cis-Retinoic Acid
13 cis retinoic acid
13-RA
13-cis RA
13-cis retinoic acid
13-cis-Retinoate
13-cis-Retinoic acid
13-cis-Vitamin A acid
13-cis-Vitamin a acid
3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)2-cis-4-trans-6-trans-8-trans-nonatetraenoic acid
4-09-00-02388 (Beilstein Handbook Reference)
4759-48-2
97950-17-9
AC-15388
AC1NQZZ4
Accutane
Accutane (TN)
Ambap302-79-4
Amnesteem
BML2-E07
BPBio1_000080
BRD-K76723084-001-05-9
BRN 1885770
BSPBio_000072
BSPBio_001331
BSPBio_003345
CCRIS 4286
CHEBI:6067
CHEMBL547
CID5282379
CIP-Isotretinoin
CPD000471891
Claravis
D00348
D015474
EINECS 225-296-0
EU-0101081
HMS1361C13
HMS1568D14
HMS1791C13
HMS1921D08
HMS1989C13
HMS2092N07
HSDB 3929
IDI1_033801
Isotane
Isotretinoin
Isotretinoin (USP)
Isotretinoin Retinoic acid
 
Isotretinoin Zinc Salt, 13 cis Isomer
Isotretinoin Zinc Salt, 13-cis-Isomer
Isotretinoin [USAN:BAN:INN]
Isotretinoin [USAN:INN:BAN]
Isotretinoina
Isotretinoine
Isotretinoine [INN-French]
Isotretinoino
Isotretinoino [INN-Spanish]
Isotretinoinum
Isotretinoinum [INN-Latin]
Isotrex
LMPR01090021
LS-143465
Lopac0_001081
MLS001074662
MolPort-003-666-394
NCGC00094358-01
NCGC00094358-02
NCGC00094358-03
NCGC00094358-04
NCGC00094358-05
NCGC00094358-06
NCGC00094358-07
NCGC00094358-08
NCGC00094358-09
NCGC00094358-13
Neovitamin A acid
Neovitamin a acid
Prestwick2_000256
Prestwick3_000256
Prestwick_642
R 3255
R3255_SIGMA
Retinoate
Retinoic acid
Ro 4 3780
Ro 4-3780
Ro 43780
Ro-4-3780
Ro-43780
Roaccutan
Roaccutane
Roacutan
SAM002548955
SMR000471891
SPECTRUM1502013
Sotret
Sotret (TN)
Spectrum5_001795
Spectrum5_001937
Teriosal
UNII-EH28UP18IF
cis-RA
cis-Retinoate
cis-Retinoic acid
isotretinoino
9
protease inhibitorsPhase 3, Phase 2, Phase 1, Phase 05157
Synonyms:
 
protease inhibitors
10
VeliparibPhase 2, Phase 3, Phase 192912444-00-911960529
Synonyms:
(2R)-2-(7-carbamoyl-1H-benzimidazol-2-yl)-2-methylpyrrolidinium
2-((2R)-2-methylpyrrolidin-2-yl)-1H-benzimidazole-4-carboxamide
 
ABT 888
ABT-888
veliparib
11
TrioxsalenPhase 3, Phase 2, Phase 1403902-71-45585
Synonyms:
2',4,8-Trimethylpsoralen
4,5',8-Trimethylpsoralen
4,8,5'-Trimethylpsoralen
6-Hydroxy-beta,2,7-trimethyl-5-benzofuranacrylic acid, delta-lactone
Trimethylpsoralen
Trioxisaleno
 
Trioxsalen
Trioxysalen
Trioxysalene
Trioxysalenum
Trisoralen
trimethylpsoralen
trioxysalen
trisoralen
12
CamptothecinPhase 2, Phase 3, Phase 1, Phase 05697689-03-4
Synonyms:
(+)-camptothecin
(+)-camptothecine
(s)-(+)-camptothecin
 
(s)-camptothecin
20(S)-Camptothecin
21,22-Secocamptothecin-21-oic acid lactone
Camptothecine
D-camptothecin
13
FlucytosinePhase 2, Phase 3, Phase 1242022-85-73366
Synonyms:
2(1H)-Pyrimidinone, 4-amino-5-fluoro-)
2-Hydroxy-4-amino-5-fluoropyrimidine
2022-85-7
4-Amino-5-fluoro-2(1H)-pyrimidinone
4-Amino-5-fluoro-2-hydroxypyrimidine
4-Amino-5-fluoro-2-hyroxypyrimidine
4-Amino-5-fluoropyrimidin-2(1H)-one
46850_FLUKA
5-FC
5-Flucytosine
5-Fluorocystosine
5-Fluorocytosin
5-Fluorocytosine
5-Fluorocytosine-6-3H
5-Flurocytosine
5-fluoro cytosine
5987P
6-Amino-2-oxo-5-fluoropyrimidine
6-amino-5-fluoro-1H-pyrimidin-2-one
9074P
AB00513969
AC-11748
AC1L1FRT
AC1Q52OQ
AKOS004912683
AKOS005063821
Alcobon
Ancobon
Ancobon (TN)
Ancobon (tn)
Ancotil
Ancotyl
BPBio1_000956
BSPBio_000868
C4H4FN3O
CAS-2022-85-7
CHEBI:5100
CHEMBL1463
CID3366
CPD000059047
Cytosine, 5-fluoro- (6CI,7CI,8CI)
D00323
DB01099
EINECS 217-968-7
F0321
F6770_SIGMA
F7129_SIGMA
Flucitosina
 
Flucitosina [DCIT]
Flucystine
Flucytosin
Flucytosine
Flucytosine (JP15/USP/INN)
Flucytosine [USAN:INN:BAN:JAN]
Flucytosinum
Flucytosinum [INN-Latin]
Flucytosone
Fluocytosine
Fluorcytosine
Fluorocytosine
GL663142 & 4-Amino-5-fluoropyrimidin-2(1H)-one
GL663142 & 5FC
HMS1570L10
HMS2051M04
HMS2093J05
HSDB 3082
I07-0006
LS-59140
LT00771985
MLS000069463
MLS000759519
MLS001076503
MolPort-000-155-561
MolPort-001-774-493
MolPort-002-317-353
MolPort-003-990-777
NCGC00016599-01
NCI60_000093
NSC 103805
NSC103805
Prestwick0_000934
Prestwick1_000934
Prestwick2_000934
Prestwick3_000934
Ro 2-9915
Ro 29915 E/265601
Ro-2-9915
S1666_Selleck
SAM001246753
SMR000059047
SPBio_003037
STK292386
TL8001667
UNII-D83282DT06
WLN: T6MVNJ DZ EF
ZINC00896546
flucytosine
14
FluorouracilPhase 2, Phase 3, Phase 1172851-21-83385
Synonyms:
1-fluoro-1h-pyrimidine-2,4-dione
1004-03-1
1upf
2,4-Dihydroxy-5-fluoropyrimidine
2,4-Dioxo-5-fluoropryimidine
2,4-Dioxo-5-fluoropyrimidine
47576_FLUKA
4921-97-5
5 FU Lederle
5 FU medac
5 Fluorouracil
5 Fluorouracil biosyn
5 HU Hexal
5-FU
5-FU (TN)
5-FU Lederle
5-FU medac
5-Faracil
5-Fluor-2,4(1H,3H)-pyrimidindion
5-Fluor-2,4(1H,3H)-pyrimidindion [Czech]
5-Fluor-2,4-dihydroxypyrimidin
5-Fluor-2,4-dihydroxypyrimidin [Czech]
5-Fluor-2,4-pyrimidindiol
5-Fluor-2,4-pyrimidindiol [Czech]
5-Fluoracil
5-Fluoracil [German]
5-Fluoracyl
5-Fluoro-2,4(1H,3H)-pyrimidinedione
5-Fluoro-2,4-pyrimidinedione
5-Fluoropyrimidin-2,4-diol
5-Fluoropyrimidine-2,4-dione
5-Fluorouracil
5-Fluorouracil-biosyn
5-Fluoruracil
5-Fluoruracil [German]
5-Fluracil
5-Ftouracyl
5-HU Hexal
5-fluoro uracil
5-fluoro-1H-pyrimidine-2,4-dione
5-fluoropyrimidine-2,4(1H,3H)-dione
5-fluorouracil
51-21-8
5FU
79108-01-3
AC-11201
AC1L1FTE
AC1Q4N2X
AI3-25297
AKOS000119162
AKOS003237897
AccuSite
Actino-Hermal
Adrucil
Adrucil (TN)
Allergan Brand of Fluorouracil
Arumel
BB_NC-0576
BSPBio_002048
C07649
C4H3FN2O2
CCRIS 2582
CHEBI:46345
CHEMBL185
CID3385
CPD0-1327
CPD000038082
CSP Brand of Fluorouracil
Carac
Carac (TN)
Carzonal
Cinco FU
Cytosafe
D005472
D00584
DB00544
Dakota Brand of Fluorouracil
Dakota, Fluorouracile
Dermatech Brand of Fluorouracil
Dermik Brand of Fluorouracil
DivK1c_000054
EINECS 200-085-6
EU-0100536
Effluderm
Effluderm (free base)
Efudex
Efudix
Efurix
F 6627
F0151
F6627_SIGMA
F8423_SIGMA
FT-0082524
FU
Ferrer Brand of Fluorouracil
Fiverocil
Fluoro Uracil
Fluoro Uracile ICN
Fluoro-Uracile ICN
Fluoro-uracile
Fluoro-uracilo
Fluoroblastin
Fluoroplex
Fluoroplex (TN)
Fluorouracil
Fluorouracil (JP15/USP/INN)
Fluorouracil GRY
Fluorouracil Mononitrate
Fluorouracil Monopotassium Salt
Fluorouracil Monosodium Salt
Fluorouracil Potassium Salt
Fluorouracil Teva Brand
Fluorouracil [USAN:INN:BAN:JAN]
 
Fluorouracil-GRY
Fluorouracile
Fluorouracile Dakota
Fluorouracile [DCIT]
Fluorouracilo
Fluorouracilo Ferrer Far
Fluorouracilo [INN-Spanish]
Fluorouracilum
Fluorouracilum [INN-Latin]
Fluoruracil
Fluouracil
Flurablastin
Fluracedyl
Fluracil
Fluracilum
Fluri
Fluril
Fluro Uracil
Fluroblastin
Flurodex
Flurouracil
Flurox
Ftoruracil
Gry Brand of Fluorouracil
HMS1920O18
HMS2090I04
HMS2091F19
HMS500C16
HSDB 3228
Haemato Brand of Fluorouracil
Haemato fu
Haemato-fu
Hexal Brand of Fluorouracil
I07-0022
ICN Brand of Fluorouracil
IDI1_000054
IN1335
KBio1_000054
KBio2_001321
KBio2_003889
KBio2_006457
KBio3_001268
KBioGR_001253
KBioSS_001321
Kecimeton
LS-153
Lopac-F-6627
Lopac0_000536
MLS000069498
MLS002415705
MolPort-000-156-102
MolPort-003-990-447
MolPort-004-758-143
MolPort-004-758-144
MolPort-005-861-486
NCGC00015442-01
NCGC00015442-03
NCGC00015442-10
NCGC00091349-01
NCGC00091349-02
NCGC00091349-03
NCGC00091349-04
NCGC00091349-05
NCGC00091349-07
NCGC00091349-08
NCI60_001652
NINDS_000054
NSC 19893
NSC-19893
NSC19893
Neocorp Brand of Fluorouracil
Neofluor
Onkofluor
Onkoworks Brand of Fluorouracil
Phthoruracil
Phtoruracil
Queroplex
Ribofluor
Riemser Brand of Fluorouracil
Ro 2-9757
Ro-2-9757
Roche Brand of Fluorouracil
S1209_Selleck
SAM002264615
SMR000038082
SPBio_000291
SPECTRUM1500305
STK297802
Spectrum2_000076
Spectrum3_000434
Spectrum4_000557
Spectrum5_000718
Spectrum_000841
T5233394
TL8006093
Teva Brand of Fluorouracil
Timazin
U 8953
U-8953
UNII-U3P01618RT
UPCMLD-DP130
UPCMLD-DP130:001
URF
Ulup
WLN: T6MVMVJ EF
ZINC00897110
biosyn Brand of Fluorouracil
fluorouracil
inhibits thymilidate synthetase
medac Brand of Fluorouracil
nchembio.90-comp3
nchembio809-comp6
ribosepharm Brand of Fluorouracil
tetratogen
15
CediranibPhase 3, Phase 2, Phase 1919933475
Synonyms:
288383-20-0
4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-(3-pyrrolidin-1-ylpropoxy)quinazoline
4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline
790713-41-6
AKOS005145767
AZD 2171
AZD-2171
AZD2171
AZD2171, Recentin, Cediranib
CHEMBL491473
CID9933475
 
Cediranib
Cediranib (USAN/INN)
Cediranib maleate
D08881
EC-000.2328
Kinome_3318
M6294
NSC-732208
Recentin
S1017_Selleck
UNII-NQU9IPY4K9
ZD-2171
cediranib
16
CarboplatinPhase 2, Phase 3, Phase 1194241575-94-410339178, 498142, 38904
Synonyms:
(SP-4-2)-diammine[cyclobutane-1,1-dicarboxylato(2-)-kappa(2)O,O']platinum
/h1-3H2,(H,7,8)(H,9,10)
/q
1,1-Cyclobutanedicarboxylate diammine platinum (II)
1,1-Cyclobutanedicarboxylate diammine platinum(II)
2*-1
2*1H2
41575-94-4
70903-55-8
AC-1457
AC1L8I6U
Ambap41575-94-4
BSPBio_003145
C 2538
C2043
C2538_SIGMA
C6H10N2O4Pt
CBDCA
CCRIS 3404
CHEBI:31355
CHEMBL1351
CHEMBL288376
CID10339178
CID2567
CID38904
CID426756
CID498142
CID5352133
CID6398587
CID6603770
Carbopaltin
Carboplatin
Carboplatin (JAN/USP/INN)
Carboplatin (USAN)
Carboplatin [USAN:INN:BAN:JAN]
Carboplatine
Carboplatine [French]
Carboplatino
Carboplatino [Spanish]
Carboplatinum
Carboplatinum [Latin]
Cbdca
Cyclobutane-1,1-dicarboxylate
D01363
DB00958
Diammine(1,1-cyclobutanedicarboxylato)platinum (II)
Diammine(cyclobutane-1,1-dicarboxylato(2-)-O,O')platinum
Diammine-1,1-cyclobutane dicarboxylate platinum II
DivK1c_000892
EINECS 255-446-0
EU-0100230
Ercar
HMS1921J16
HMS2090M05
HMS2092B22
HMS502M14
HSDB 6957
I14-2390
IDI1_000892
IUPAC: Azane
InChI=1/C6H8O4.2H2N.Pt/c7-4(8)6(5(9)10)2-1-3-6
 
JM 8
JM-8
KBio1_000892
KBio2_002009
KBio2_004577
KBio2_007145
KBio3_002645
KBioGR_000713
KBioSS_002009
LS-117689
Lopac-C-2538
Lopac0_000230
MolPort-003-665-501
MolPort-003-845-609
NCGC00015223-01
NCGC00093695-01
NCGC00094961-01
NCGC00094961-02
NCGC00094961-03
NCGC00162099-01
NCGC00162099-02
NCGC00167800-01
NCGC00178242-01
NINDS_000892
NSC 201345
NSC 241240
NSC-241240
NSC201345
NSC241240
Paraplatin
Paraplatin (TN)
Paraplatin, Carboplatin
Paraplatin-AQ
Platinum(+2) Cation
Platinum(II), (1, 1-cyclobutanedicar
Platinum, diammine(1,1-cyclobutanedicarboxylato(2-)-O,O')-, (SP-4-2)
Platinum, {diammine[1,1-cyclobut
S1215_Selleck
SPBio_000716
SPECTRUM1502106
Spectrum2_000898
Spectrum3_001503
Spectrum4_000337
Spectrum5_001094
Spectrum_001529
UNII-BG3F62OND5
azanide
carboplatin
cis -Diammine[1,1-cyclobutane-dicarboxylato] platinum
cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(II)
cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(ii)
cis-Diamine(1,1-cyclobutanedicarboxylato)platinum(II)
cis-Diamine[1,1-cyclobutanedicarboxylato]platinum(II)
cis-Diammine(1,1-cyclobutanedicarboxylato) platinum
cis-Diammine(1,1-cyclobutanedicarboxylato)platinum
cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II)
cis-Diammine(cyclobutanedicarboxylato)platinum II
cyclobutane-1,1-dicarboxylic acid
diammine[cyclobutane-1,1-dicarboxylato(2-)-k2O1,O1]platinum
nchembio.573-comp10
nchembio773-comp2
nchembio873-comp3
platinum(2+)
17
CyclophosphamidePhase 2, Phase 3, Phase 1275650-18-0, 6055-19-22907
Synonyms:
(+-)-Cyclophosphamide
(-)-Cyclophosphamide
(RS)-Cyclophosphamide
1-(bis(2-chloroethyl)amino)-1-oxo-2-aza-5-oxaphosphoridine
1-Bis(2-chloroethyl)amino-1-oxo-2-aza-5-oxaphosphoridin
2-[Bis(2-chloroethylamino)]-tetrahydro-2H-1,3,2-oxazaphosphorine-2-oxide
4-Hydroxy-cyclophosphan-mamophosphatide
50-18-0
60007-95-6
6055-19-2 (monohydrate)
75526-90-8
AC1L1EQQ
AI3-26198
ASTA
ASTA B518
Anhydrous cyclophosphamide
Asta B 518
B 518
B-518
BRN 0011744
BSPBio_002099
Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester
C 0768
C07888
C7H15Cl2N2O2P
CB 4564
CB-4564
CCRIS 188
CHEBI:4027
CHEMBL32520
CHEMBL88
CID2907
CP
CPA
CTX
CY
Ciclofosfamida
Ciclofosfamida [INN-Spanish]
Ciclofosfamide
Ciclophosphamide
Ciclophosphamide [INN]
Clafen
Claphene
Cycloblastin
Cyclophosphamid
Cyclophosphamide
Cyclophosphamide (INN)
Cyclophosphamide (TN)
Cyclophosphamide (anhydrous form)
Cyclophosphamide (anhydrous)
Cyclophosphamide Monohydrate
Cyclophosphamide Sterile
Cyclophosphamide anhydrous
Cyclophosphamide, (+-)-Isomer
Cyclophosphamides
Cyclophosphamidum
Cyclophosphamidum [INN-Latin]
Cyclophosphan
Cyclophosphane
Cyclophosphanum
Cyclophosphoramide
Cyclostin
Cyklofosfamid
Cyklofosfamid [Czech]
Cytophosphan
Cytophosphane
Cytoxan
Cytoxan (TN)
Cytoxan Lyoph
D,L-Cyclophosphamide
D07760
 
DB00531
DivK1c_000246
EINECS 200-015-4
EU-0100238
Endoxan
Endoxan R
Endoxan-Asta
Endoxana
Endoxanal
Endoxane
Enduxan
Genoxal
HMS2090A12
HSDB 3047
Hexadrin
IDI1_000246
KBio1_000246
KBio2_001338
KBio2_003906
KBio2_006474
KBio3_001319
KBioGR_000888
KBioSS_001338
LS-1302
LS-99787
Ledoxina
Lopac-C-0768
Lopac0_000238
Lyophilized Cytoxan
Mitoxan
MolPort-001-783-420
N,N-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide
N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
NCGC00015209-01
NCGC00015209-03
NCGC00015209-06
NCGC00091741-02
NCGC00091741-03
NCI-C04900
NCI60_002097
NINDS_000246
NSC 26271
NSC-26271
NSC26271
NSC273033
NSC273034
Neosar
Occupation, cyclophosphamide exposure
Procytox
RCRA waste no. U058
Rcra Waste Number U058
Rcra waste number U058
Revimmune
S1217_Selleck
SK 20501
SPBio_001071
STK177249
STOCK2S-91217
Semdoxan
Sendoxan
Senduxan
Spectrum2_001146
Spectrum3_000370
Spectrum4_000304
Spectrum5_000795
Spectrum_000858
UNII-6UXW23996M
WLN: T6MPOTJ BO BN2G2G
Zyklophosphamid
Zyklophosphamid [German]
bis(2-Chloroethyl)phosphami de cyclic propanolamide
bis(2-Chloroethyl)phosphamide cyclic propanolamide ester
cyclophosphamide
18
EtoposidePhase 2, Phase 3, Phase 1, Phase 0121033419-42-036462
Synonyms:
(-)-Etoposide
121471-01-0
136598-18-0
201594-04-9
33419-42-0
35317-32-9
4'-Demethyl-epipodophyllotoxin 9-[4,6-O-(R)-ethylidene-beta-D-glucopyranoside
4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-ethylidene-beta-D-glucopyranoside)
4'-Demethylepipodophyllotoxin 9-(4,6-O-ethylidene-beta-D-glucopyranoside)
4'-Demethylepipodophyllotoxin ethylidene-.beta.-D-glucoside
4'-O-Demethyl-1-O-(4,6-O-ethylidene-beta-D-glucopyranosyl)epipodophyllotoxin
4-Demethylepipodophyllotoxin beta-D-ethylideneglucoside
4-Demethylepipodophyllotoxin-.beta.-D-ethylideneglucoside
51854-34-3
76576-58-4
9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-D)-1,3-dioxol-6(5ah)-one
AB00438905
AC1L1FN8
AC1L1VT3
AC1L6246
AC1NR4OG
AC1O4WGG
AC1O7M1N
AC1Q47JJ
Ambap33419-42-0
BPBio1_000673
BRD-K37798499-001-02-5
BSPBio_000611
Bio1_000489
Bio1_000978
Bio1_001467
C01576
CCRIS 2392
CHEBI:4911
CHEBI:588795
CHEMBL44657
CID11758093
CID284997
CID3310
CID36462
CID5284558
CID6419930
CID6610299
CPD000112002
D00125
DB00773
DEMETHY-EPIPODOPHYLLOTOXIN,ETHYLIDENE GLUCOSIDE,
Demethyl Epipodophyllotoxin Ethylidine Glucoside
Demethyl-epiodophyllotoxin ethylidene glucoside
Demethylepipodophyllotoxin-beta-D-ethylideneglucoside
E0675
E1383_SIGMA
EINECS 251-509-1
EPE
EPEG
ETOP
Epipodophyllotoxin
Epipodophyllotoxin VP-16213
Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-.beta.-D-glucopyranoside
Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-beta-D-glucopyranoside
Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-beta-D-glucopyranoside (8CI)
Epipodophyllotoxin, 4'-demethyl-, 9-(4,6-O-ethylidene-.beta.-D-glucopyranoside)
Epipodophyllotoxin, 4'-demethyl-, 9-(4,6-O-ethylidene-beta-D-glucopyranoside)
Eposide
Eposin
 
Eposin, Vepesid, VP-16, Toposar, Etoposide
Etopol
Etopophos
Etopophos (phosphate salt)
Etoposid
Etoposide
Etoposide (JP15/USP/INN)
Etoposide (VP16)
Etoposide [USAN:INN:BAN:JAN]
Etoposido
Etoposido [INN-Spanish]
Etoposidum
Etoposidum [INN-Latin]
Etosid
HMS1569O13
HMS2052N05
HMS2089F14
HSDB 6517
I06-0248
KBioSS_002410
LS-1214
Lastet
MLS000049957
MLS001074951
MLS001424283
MLS002153463
MLS002207239
MLS002222184
MolPort-003-983-431
MolPort-004-905-001
MolPort-004-955-161
NCGC00025056-02
NChemBio.2007.10-comp19
NK 171
NSC 141540
NSC-141540
NSC141540
Prestwick0_000396
Prestwick1_000396
Prestwick2_000396
Prestwick3_000396
Prestwick_211
S1225_Selleck
SAM001246880
SMR000112002
SPBio_002532
ST056353
Toposar
UNII-6PLQ3CP4P3
VP 16
VP 16 (pharmaceutical)
VP 16-213
VP 16213
VP-16
VP-16-213
VePESID (TN)
VePesid
Vepesid
Vepesid J
Vepeside
ZINC03830818
ZINC03938684
Zuyeyidal
etoposide
nchembio.573-comp8
nchembio873-comp2
trans-Etoposide
19TRABEDERSENPhase 3, Phase 23
20
Aminolevulinic acidPhase 3, Phase 2, Phase 1150106-60-5137
Synonyms:
106-60-5
35BEC718-C970-426A-9859-BF58284C60B4
5-ALA
5-Amino-4-oxo-Pentanoate
5-Amino-4-oxo-Pentanoic acid
5-Amino-4-oxopentanoate
5-Amino-4-oxopentanoic acid
5-Amino-4-oxovalerate
5-Amino-4-oxovaleric acid
5-Amino-Levulinate
5-Amino-Levulinic acid
5-Aminolaevulinate
5-Aminolaevulinic acid
5-Aminolevulinate
5-Aminolevulinic acid
5-amino-levulinate
5451-09-2
AC-054
AC1L18K9
AKOS003587520
ALA
ALA-PDT
Aladerm
Amino-levulinic acid
Aminolevulinate
Aminolevulinic
Aminolevulinic acid
BIDD:GT0260
BSPBio_003407
C00430
CCRIS 8958
CHEBI:17549
CHEMBL601
CID137
CPD000857229
 
D07567
DALA
DB00855
DivK1c_006954
EINECS 203-414-1
I14-10101
KBio1_001898
KBio2_002062
KBio2_004630
KBio2_007198
KBio3_002627
KBioGR_001176
KBioSS_002062
Kerastick
LMFA01100055
LS-101793
Levulinic acid, 5-amino- (8CI)
MLS001333097
MLS001333098
MolPort-001-788-423
NCGC00178086-01
Pentanoic acid, 5-amino-4-oxo- (9CI)
SAM002589919
SMR000857229
SPBio_001843
ST50819610
SpecPlus_000858
Spectrum2_001662
Spectrum3_001654
Spectrum4_000618
Spectrum5_001505
Spectrum_001582
UNII-88755TAZ87
delta-ALA
delta-Aminolevulinate
delta-Aminolevulinic acid
delta-aminolevulinic acid
21topoisomerase I inhibitorsPhase 2, Phase 3, Phase 1, Phase 01313
22EtherPhase 3, Phase 2, Phase 155
23
IrinotecanPhase 2, Phase 3, Phase 1, Phase 0106297682-44-5, 100286-90-660838
Synonyms:
(+)-Irinotecan
(4S)-4,11-DIETHYL-4-HYDROXY-3,14-DIOXO-3,4,12,14-TETRAHYDRO-1H-PYRANO[3',4':6,7]INDOLIZINO[1,2-B]QUINOLIN-9-YL 1,4'-BIPIPERIDINE-1'-CARBOXYLATE
(4S)-4,11-Diethyl-4-hydroxy-3,14-dioxo-4,12-dihydro-1H-pyrano[3,4-f]quinolino[2,3-a]indolizin-9-yl 4-piperidylpiperidinecarboxylate
1u65
97682-44-5
AC-7469
AC1L1U0Z
AC1Q6PGI
BRD-K08547377-003-02-4
BSPBio_002346
Bio-0054
Biotecan
Biotecan (TN)
C16641
C33H38N4O6
CHEBI:105985
CHEMBL481
CID60838
CP0
Campothecin-11
Campto
Camptosar
 
Camptosar, Campto, CPT-11, Irinotecan
Camptothecin-11
D08086
DB00762
FT-0083650
HSDB 7607
IRINOTECAN HYDROCHLORIDE Trihydrate
IRINOTECAN, CPT-11
Irinotecan (INN)
Irinotecan Hcl
Irinotecan Hydrochloride
Irinotecan Hydrochloride Trihydrate
Irinotecan [INN:BAN]
Irinotecan hydrochloride
Irinotecanum
Irinotecanum [INN-Latin]
LS-44589
NCI60_005051
NSC728073
S1198_Selleck
TL8006026
UNII-7673326042
irinotecan
24
DonepezilPhase 3, Phase 2275120014-06-43152
Synonyms:
( inverted exclamation markA)-E 2020
1-Benzyl-4-[(5,6-dimethoxy-1-oxoindan-2-yl)methyl]piperidine
120014-06-4
2-[(1-benzylpiperidin-4-yl)methyl]-5,6-dimethoxy-2,3-dihydroinden-1-one
2-[(1-benzylpiperidin-4-yl)methyl]-5,6-dimethoxyindan-1-one
AB1004836
AC-6969
AC1L1FAE
AKOS000277311
Aricept
Aricept ODT
C24H29NO3
CHEBI:53289
CHEMBL502
CID3152
D07869
DB00843
Domepezil
Donaz
Donaz (TN)
 
Donepezil
Donepezil (INN)
Donepezil [INN:BAN]
Donepezil hydrochloride
Donepezilo
Donepezilum
Eranz
I06-0343
KBio2_002144
KBio2_004712
KBio2_007280
KBioSS_002144
LS-81819
MolPort-000-881-588
MolPort-003-847-014
NCGC00167537-01
Oprea1_188452
Spectrum5_001662
Spectrum_001664
TL8000531
UNII-8SSC91326P
25
LeflunomidePhase 36675706-12-63899
Synonyms:
210165-51-8
4-Isoxazolecarboxamide, 5-methyl-N-(4-(trifluoromethyl)phenyl
4-isoxazolecarboxamide,5-methyl-N-(4-(trifluoromethyl)phenyl)
5-Methyl-N-(4-(trifluoromethyl)phenyl)-4-isoxazolecarboxamide
5-Methylisoxazole-4-(4-trifluoromethyl)carboxanilide
5-Methylisoxazole-4-(4-trifluoromethylcarboxanilide)
5-Methylisoxazole-4-carboxylic acid (4-trifluoromethyl)anilide
5-methyl-N-[4-(trifluoromethyl)phenyl]-1,2-oxazole-4-carboxamide
5-methyl-N-[4-(trifluoromethyl)phenyl]-4-isoxazolecarboxamide
5-methyl-N-[4-(trifluoromethyl)phenyl]isoxazole-4-carboxamide
75706-12-6
A77 1486
AB00052389
AC-6796
AC1L1GYK
AC1Q2EVA
AKOS000265193
AP-501/42475599
Arava
Arava (TN)
Arava, Leflunomide
Aventis Behring Brand of Leflunomide
Aventis Brand of Leflunomide
Aventis Pharma Brand of Leflunomide
BIDD:PXR0189
BPBio1_000930
BRD-K78692225-001-03-9
BSPBio_000844
C045463
C07905
CAS-75706-12-6
CHEBI:6402
CHEMBL960
CID3899
D00749
DB01097
DivK1c_000916
EU-0100649
HMS1570K06
HMS1922M06
HMS2090O12
HMS502N18
HSDB 7289
HWA 486
HWA-486
Hoechst Brand of Leflunomide
I06-2131
IDI1_000916
KBio1_000916
KBio2_000802
KBio2_003370
KBio2_005938
KBioSS_000802
L 5025
L5025_SIGMA
 
LS-86580
Leflunomid
Leflunomida
Leflunomida [INN-Spanish]
Leflunomide
Leflunomide (JAN/USAN/INN)
Leflunomide [USAN:INN]
Leflunomidum
Leflunomidum [INN-Latin]
Lefunomide
Lefunomide [INN-Spanish]
Lefunomide [Inn-Spanish]
Lopac-L-5025
Lopac0_000649
MLS-0003109.0001
MLS000069648
MLS001076267
MolPort-002-345-613
N-(4'-Trifluoromethylphenyl)-5-methylisoxazole-4-carboxamide
N-(4-trifluoromethyphenyl)-5-methylisoxazole-4-carboxamide
NCGC00015610-01
NCGC00015610-02
NCGC00015610-03
NCGC00015610-07
NCGC00015610-12
NCGC00022625-03
NCGC00022625-04
NCGC00022625-05
NCGC00022625-06
NCGC00022625-07
NCGC00022625-08
NINDS_000916
NSC677411
Prestwick0_000772
Prestwick1_000772
Prestwick2_000772
Prestwick3_000772
Prestwick_87
RS-34821
S1247_Selleck
SMR000058209
SPBio_002783
SPECTRUM1503927
SU 101
SU 101 (pharmaceutical)
SU-101
SU101
Spectrum5_000850
Spectrum_000322
TL8005179
UNII-G162GK9U4W
ZINC00004840
alpha,alpha,alpha-Trifluoro-5-methyl-4-isoxazolecarboxy-P-toluidide
alpha,alpha,alpha-Trifluoro-5-methyl-4-isoxazolecarboxy-p-toluidide
leflunomide
lefunamide
26
ProcarbazinePhase 3, Phase 2, Phase 169671-16-94915
Synonyms:
1-Methyl-2-(P-(isopropylcarbamoyl)benzyl)hydrazine
1-Methyl-2-(p-(isopropylcarbamoyl)benzyl)hydrazine
2-(P-Isopropylcarbamoylbenzyl)-1-methylhydrazine
2-(p-Isopropylcarbamoylbenzyl)-1-methylhydrazine
366-70-1 (mono-hydrochloride)
4-((2-Methylhydrazino)methyl)-N-isopropylbenzamide
4-[(2-methylhydrazinyl)methyl]-N-propan-2-ylbenzamide
671-16-9
AC-4547
AC1L1J8E
Ambap671-16-9
BIDD:GT0183
BPBio1_001369
BRN 0958270
BSPBio_001244
Benzamide, N-(1-methylethyl)-4-((2-methylhydrazino)methyl)- (9CI)
C07402
C12H19N3O
CAS-366-70-1
CB 400-497
CCRIS 2389
CHEMBL1321
CID4915
D08423
DB01168
EINECS 211-582-2
HMS2090J09
HSDB 3250
I01-8931
IBZ
Ibenzmethyzin
Ibenzmethyzine
LS-7671
MBH
MIH
MolPort-005-940-370
N-(1-Methylethyl)-4-((2-methylhydrazino)methyl)benzamide
 
N-(1-Methylethyl)-4-[(2-methylhydrazino)methyl]benzamide
N-4-Isopropylcarbamoylbenzyl-N'-methylhydrazine
N-4-Isopropylcarbamoylbenzyl-n'-methylhydrazine
N-Isopropyl-4-[(2-methylhydrazino)methyl]benzamide
N-Isopropyl-P-(2-methylhydrazinomethyl)-benzamide
N-Isopropyl-alpha-(2-methylhydrazino)-P-toluamide
N-Isopropyl-alpha-(2-methylhydrazino)-p-toluamide
N-Isopropyl-p-(2-methylhydrazinomethyl)-benzamide
NCGC00016438-01
NCGC00016438-02
NCI60_041703
NCIOpen2_004074
NSC-77213
Natulan
Natulanar
P-(2-Methylhydrazinomethyl)-N-isopropylbenzamide
PCX
Prestwick0_001112
Prestwick1_001112
Prestwick2_001112
Prestwick3_001112
Procarbazin
Procarbazin [German]
Procarbazina
Procarbazina [INN-Spanish]
Procarbazine (INN)
Procarbazine Monohydrochloride
Procarbazine [INN:BAN]
Procarbazinum
Procarbazinum [INN-Latin]
Ro 4-6467
Ro 4-6467/1
SPBio_003112
SRI-10847
UNII-35S93Y190K
p-(2-Methylhydrazinomethyl)-N-isopropylbenzamide
p-(N'-Methylhydrazinomethyl)-N-isopropylbenzamide
procarbazine
27
LomustinePhase 3, Phase 2, Phase 17913010-47-43950
Synonyms:
(Chloro-2-ethyl)-1-cyclohexyl-3-nitrosourea
(Cloro-2-etil)-1-cicloesil-3-nitrosourea
(Cloro-2-etil)-1-cicloesil-3-nitrosourea [Italian]
1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea
1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea [Chloroethyl nitrosoureas]
1-(2-Chloroethyl)-3-cyclohexylnitrosourea
13010-47-4
AC-10564
AC1L1H2T
AI3-52779
BRN 2125058
Belustine
Bristol Myers Squibb Brand of Lomustine
Bristol-Myers Squibb Brand of Lomustine
C9H16ClN3O2
CCNU
CCNU [Chloroethyl nitrosoureas]
CCRIS 860
CHEMBL514
CID3950
CINU
Cecenu
CeeNU
CeeNU (TN)
CeeNU, CCNU, Lomustine
Chloroethylcyclohexylnitrosourea
Cyclohexyl chloroethyl nitrosourea
D00363
D008130
DB01206
EINECS 235-859-2
FT-0083566
 
HMS2090A17
HSDB 6519
I06-0087
ICIG 1109
LS-728
Lomustina
Lomustina [INN-Spanish]
Lomustine (USAN/INN)
Lomustine [USAN:BAN:INN]
Lomustine medac Brand
Lomustinum
Lomustinum [INN-Latin]
MolPort-001-768-818
N-(2-Chloroethyl)-N'-cyclohexyl-N-nitrosourea
N-(2-Chloroethyl)-n'-cyclohexyl-N-nitrosourea
NCGC00167466-01
NCI-C04740
NCI60_041743
NCIMech_000220
NPFAPI-06
NSC 79037
NSC-79037
NSC79037
OR5087
RB 1509
Rhone Poulenc Rorer Brand of Lomustine
Rhone-Poulenc Rorer Brand of Lomustine
S1840_Selleck
SRI 2200
UNII-7BRF0Z81KG
WLN: L6TJ AMVNNO&2G
ZINC03831006
lomustine
medac Brand of Lomustine
28Imatinib MesylatePhase 3, Phase 2, Phase 1588123596
29
HydroxyureaPhase 3, Phase 2, Phase 1208127-07-13657
Synonyms:
1-HYDROXYUREA
127-07-1
4-03-00-00170 (Beilstein Handbook Reference)
55291_FLUKA
AC1L1GF8
AC1Q4ZXK
AI3-51139
BB_SC-7256
BRN 1741548
BSPBio_002164
Bio1_000451
Bio1_000940
Bio1_001429
Biosupressin
C07044
CCRIS 958
CHEBI:44423
CHEMBL467
CID3657
Carbamohydroxamic Acid
Carbamohydroxamic acid
Carbamohydroximic Acid
Carbamohydroximic acid
Carbamohydroxyamic Acid
Carbamohydroxyamic acid
Carbamoyl Oxime
Carbamoyl oxime
Carbamyl Hydroxamate
Carbamyl hydroxamate
Carrbamoyl Oxime
D00341
D006918
DB01005
DRG-0253
DivK1c_000556
Droxia
Droxia (TM)
Droxia (TN)
E0723DBA-5AF3-49D1-B5F6-59420AB87AC9
EINECS 204-821-7
EU-0100596
FT-0083575
H 8627
H0310
H20210
H8627_SIGMA
HMS1920F09
HMS2091L17
HMS501L18
HSDB 6887
HU
HYDREA (TN)
HYDROXY-UREA
Hidrix
Hidroxicarbamida
Hidroxicarbamida [INN-Spanish]
Hydrea
Hydrea (TM)
Hydrea, Biosupressin, Cytodrox, Hydroxyurea
Hydreia
Hydroxicarbamidum
Hydroxycarbamid
Hydroxycarbamide
Hydroxycarbamide (JAN/INN)
Hydroxycarbamidum
Hydroxycarbamidum [INN-Latin]
Hydroxycarbamine
Hydroxyharnstoff
Hydroxyharnstoff [German]
Hydroxylurea
Hydroxyurea
Hydroxyurea (D4)
Hydroxyurea (USP)
Hydroxyurea [USAN:BAN]
Hydroxyurea(d4)
 
Hydura
Hydurea
I05-0250
IDI1_000556
Idrossicarbamide
Idrossicarbamide [DCIT]
Idrossicarbamide [Dcit]
KBio1_000556
KBio2_001389
KBio2_003957
KBio2_006525
KBio3_001384
KBioGR_000383
KBioSS_001389
LS-709
Litaler
Litalir
Lopac-H-8627
Lopac0_000596
MLS001332381
MLS001332382
MLS002153389
MolMap_000029
MolPort-000-003-971
Mylocel
N-(Aminocarbonyl) Hydroxyamine
N-Carbamoylhydroxylamine
N-HYDROXY UREA
N-Hydroxymocovina
N-Hydroxymocovina [Czech]
N-Hydroxyurea
NCGC00015520-01
NCGC00015520-02
NCGC00015520-07
NCGC00093974-01
NCGC00093974-02
NCGC00093974-03
NCGC00093974-04
NCGC00093974-05
NCI C04831
NCI-C04831
NCI60_002773
NCIMech_000139
NHY
NINDS_000556
NSC 32065
NSC32065
Onco-Carbide
Onco-carbide
Oncocarbide
Oxyurea
S-phase/G-1 interface inhibitor
S1896_Selleck
SK 22591
SMR000059149
SPBio_000247
SPECTRUM1500344
SQ 1089
SQ-1089
Siklos
Spectrum2_000064
Spectrum3_000462
Spectrum4_000012
Spectrum5_000836
Spectrum_000909
Sterile Urea
TL8000673
UNII-X6Q56QN5QC
Ureaphil
WLN: ZVMQ
carbamide oxide
hydroxyaminomethanamide
hydroxyurea
nchembio.573-comp3
nchembio.90-comp4
nchembio749-comp3
tetratogen: inhibits ribonucleoside diphosphate reductase
30
CarmustinePhase 3, Phase 2, Phase 1211154-93-82578
Synonyms:
1,3-BIS(CHLOROETHYL)-1-NITROSOUREA
1,3-Bis(.beta.-chloroethyl)-1-nitrosourea
1,3-Bis(2-chloroethyl)-1-nitrosourea
1,3-Bis(2-chloroethyl)nitrosourea
1,3-Bis(beta-chloroethyl)-1-nitrosourea
154-93-8
AC-10563
AC1L1DZQ
AI3-52216
BCNU
BCNU [Chloroethyl nitrosoureas]
BRN 2049744
Becenum
Becenun
Bi CNU
BiCNU
BiCNU (TN)
Bicnu (tn)
Bio-0118
Bis(2-chloroethyl)1-nitrosourea
Bis(2-chloroethyl)nitrosourea
Bis(chloroethyl)nitrosourea
Bis-N,N'-(chloroethyl)nitrosourea
Bischlorethylnitrosourea
Bischlorethylnitrosurea
Bischloroethyl nitrosourea
Bischloroethyl nitrosourea [Chloroethyl nitrosoureas]
Bischloroethylnitrosourea
C 0400
C0400_SIGMA
C5H11Cl2N3O2
CCRIS 810
CHEBI:3423
CHEMBL513
CID2578
Carmubris
Carmustin
Carmustina
Carmustina [INN-Spanish]
Carmustine
Carmustine (USAN/INN)
Carmustine [USAN:INN:BAN]
Carmustinum
Carmustinum [INN-Latin]
D002330
D00254
DB00262
DTI 015
DivK1c_000835
EINECS 205-838-2
EU-0100188
 
FDA 0345
FIVB
FT-0083563
Gliadel
Gliadel Wafer
Gliadel, BCNU, NSC-409962, Becenun, Carmustine
HMS2092J22
HMS502J17
I14-11976
IDI1_000835
KBio1_000835
KBio2_000745
KBio2_003313
KBio2_005881
KBioGR_001296
KBioSS_000745
LS-890
Lopac-C-0400
Lopac0_000188
MLS001333962
MolPort-003-665-505
N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA
N,N'-Bis(2-chloroethyl)-N-nitrosourea
NCGC00015204-01
NCGC00015204-02
NCGC00015204-06
NCGC00093665-01
NCGC00093665-02
NCGC00093665-03
NCGC00093665-04
NCI-C04773
NCI60_003931
NINDS_000835
NSC 409962
NSC-409962
NSC409962
Nitrumon
Prestwick_997
S1521_Selleck
SK 27702
SMR000058426
SRI 1720
STK624770
Spectrum4_000888
Spectrum5_000920
Spectrum_000265
UNII-U68WG3173Y
WLN: ONN2GVM2G
ZINC03830387
bis-chloroethylnitrosourea
carmustine
carmustine in ethanol
31
chloroquinePhase 3, Phase 2, Phase 114554-05-72719
Synonyms:
( -)-Chloroquine
(+)-Chloroquine
(-)-Chloroquine
(R)-(-)-Chloroquine
3377 RP opalate
3545-67-3
50-63-5
54-05-7
56598-66-4
58175-86-3
58175-87-4
7-Chloro-4-((4-(diethylamino)-1-methylbutyl)amino)quinoline
7-Chloro-4-[[4-(diethylamino)-1-methylbutyl]amino]quinoline
AB00053436
AC1L1EB8
AC1Q2ZA7
AC1Q2ZA8
Amokin
Aralen
Aralen HCl
Arechin
Arechine
Arequin
Arolen
Arthrochin
Artrichin
Avlochlor
Avloclor
BPBio1_000655
BRD-A91699651-065-01-1
BRN 0482809
BSPBio_000595
BSPBio_002001
Bemaco
Bemaphate
Bemasulph
Benaquin
Bipiquin
C07625
C18H26ClN3
CCRIS 3439
CHEBI:3638
CHEMBL76
CID2719
CQ
CU-01000012392-2
Capquin
Chemochin
Chingamin
Chloraquine
Chlorochin
Chlorochine
Chlorochinum
Chloroin
Chloroquin
Chloroquina
Chloroquine
Chloroquine (USP/INN)
Chloroquine (VAN)
Chloroquine Bis-Phosphoric Acid
Chloroquine Phosphate
Chloroquine [USAN:INN:BAN]
Chloroquine phosphate
Chloroquinium
Chloroquinum
Chloroquinum [INN-Latin]
Chlorquin
Cidanchin
Clorochina
Clorochina [DCIT]
Cloroquina
Cloroquina [INN-Spanish]
Cocartrit
D02366
DB00608
Dawaquin
Delagil
Dichinalex
DivK1c_000404
EINECS 200-191-2
Elestol
Gontochin
Gontochin phosphate
HMS2090O03
HSDB 3029
Heliopar
Hydroxychloroquine Sulfate
IDI1_000404
Imagon
 
Ipsen 225
Iroquine
KBio1_000404
KBio2_000592
KBio2_003160
KBio2_005728
KBio3_001221
KBioGR_000778
KBioSS_000592
Khingamin
Klorokin
LS-141726
Lapaquin
Lopac0_000296
Malaquin
Malaquin (*Diphosphate*)
Malaren
Malarex
Mesylith
Miniquine
MolMap_000009
MolPort-001-783-623
N(4)-(7-chloro-4-Quinolinyl)-N(1),N(1)-diethyl-1,4-pentanediamine
N4-(7-Chloro-4-quinolinyl)-N1,N1-diethyl-1,4-pentanediamine
N4-(7-chloroquinolin-4-yl)-N1,N1-diethylpentane-1,4-diamine
NCGC00015256-04
NCGC00162120-01
NCI60_000894
NINDS_000404
NSC 187208
NSC14050
NSC187208
Neochin
Nivachine
Nivaquine
Nivaquine B
Pfizerquine
Plaquenil
Prestwick0_000548
Prestwick1_000548
Prestwick2_000548
Prestwick3_000548
Quinachlor
Quinagamin
Quinagamine
Quinercyl
Quingamine
Quinilon
Quinoscan
RP 3377
RP-3377
Resochen
Resochin
Resoquina
Resoquine
Reumachlor
Reumaquin
Rivoquine
Ro 01-6014/N2
Ronaquine
Roquine
SMP2_000034
SN 6718
SN-7618
SPBio_000174
SPBio_002516
ST 21
ST 21 (pharmaceutical)
Sanoquin
Silbesan
Siragan
Solprina
Sopaquin
Spectrum2_000127
Spectrum3_000341
Spectrum4_000279
Spectrum5_000707
Spectrum_000132
Tanakan
Tanakene
Tresochin
Trochin
UNII-886U3H6UFF
W 7618
WIN 244
WLN: T66 BNJ EMY1&3N2&2 IG
chloroquine
nchembio.215-comp4
nchembio.368-comp8
nchembio.87-comp17
{4-[(7-chloroquinolin-4-yl)amino]pentyl}diethylamine
32Chloroquine diphosphatePhase 3, Phase 2, Phase 114550-63-5
33
BevacizumabPhase 3, Phase 2, Phase 1, Phase 01938216974-75-3
Synonyms:
216974-75-3
Avastin
Avastin (TN)
Bevacizumab
Bevacizumab (genetical recombination)
 
Bevacizumab (genetical recombination) (JAN)
D06409
R-435
anti-VEGF monoclonal antibody
antiVEGF
bevacizumab
34
TretinoinPhase 3, Phase 2, Phase 1218302-79-45538
Synonyms:
(all-e)-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic acid
.beta.-Retinoic acid
13497-05-7 (hydrochloride salt)
15-Apo-beta-caroten-15-oic acid
187175-63-9
1n4h
3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic acid
3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexene-1-yl)-2,4,6,8-nonatetraenoic acid (ecl)
302-79-4
5300-03-8
56573-65-0
7005-78-9
9(Z)-Retinoic acid
9-cis-RA
A-Acido (Argentina)
A-Vitaminsyre
A-Vitaminsyre [Denmark]
AC-6824
AC1L9GWO
AC1Q1J2J
AGN 100335
AGN 192013
AKOS000280845
ALRT 1057
AT-RA
ATRA
Aberel
Aberela
Aberela [Norway]
Accutane Roche
Acid A Vit (Belgium, Netherlands)
Acid, Retinoic
Acid, Vitamin A
Acid, all-trans-Retinoic
Acid, beta-all-trans-Retinoic
Acid, trans-Retinoic
Acide retinoique (French) (DSL)
Acide retinoique (french) (dsl)
Acnavit
Acnavit [Denmark]
Airol
Aknefug
Aknoten
Alitretinoin
All Trans Retinoic Acid
All Trans-Retinoic Acid
All-trans Retinoic Acid
Alltrans-retinoic acid
Amnesteem
Atra-IV
Atragen
Atralin
Avita (TN)
Avita Gel
Avitoin
Avitoin [Norway]
BAL4079
BIDD:GT0483
BIDD:PXR0081
BML2-E05
BPBio1_000082
BRN 2057223
BSPBio_000074
BSPBio_001500
Betarretin
C00777
CCRIS 3294
CCRIS 7098
CHEBI:15367
CHEMBL38
CID444795
CPD000058245
Claravis
Cordes VAS [Germany]
Cordes vas
D00094
D014212
DB00523
DB00755
DB00982
Dermairol
EINECS 206-129-0
EU-0101061
Effederm
Effederm [France]
Epi-aberel
Eudyna
HMS1361K22
HMS1568D16
HMS1791K22
HMS1921D14
HMS1989K22
HMS2089D20
HMS2092N11
HMS502N05
HSDB 2169
HSDB 7186
I04-0008
I14-2351
IDI1_000903
IDI1_033970
Isotretinoin Retinoic acid
L000833
LGD 100057
LMPR01090019
LS-1154
Lopac0_001061
Lsotretinoin
MLS000028588
MLS001076515
MLS002207234
MLS002222211
MolPort-000-883-857
NCGC00017280-06
NCGC00017280-17
NCGC00021808-04
 
NCGC00021808-05
NCGC00021808-06
NCGC00021808-07
NCGC00021808-09
NCGC00021808-14
NCGC00021808-15
NSC 122758
NSC-122758
NSC122758
Nexret
PDT-002-002
Panretin Gel
Panretyn
Potassium Salt, Tretinoin
Prestwick2_000257
Prestwick3_000257
Prestwick_424
R 2625
R0064
R2625_SIGMA
REA
RETINOIC ACID, ALL TRANS
RETINOIC acid
Renova
Renova (TN)
Retacnyl
Retin A
Retin A (TN)
Retin-A
Retin-A Micro
Retin-a
Retinoate
Retinoic acid
Retinoic acid, all-trans- (8CI)
Retinova
Retionic Acid
Retionic acid
Retisol-A
Retisol-a
Ro 1-5488
S1653_Selleck
SAM002264647
SMR000058245
SPECTRUM1502016
SR-01000000239
SR-01000000239-14
ST057075
Salt, Tretinoin Potassium
Salt, Tretinoin Sodium
Salt, Tretinoin Zinc
Sodium Salt, Tretinoin
Solage
Sotret
Spectrum5_001746
Spectrum5_001933
Stieva-A
Stieva-a
Stieva-a Forte
TRETINON
Tretin M
Tretin m
Tretinoin
Tretinoin (JAN/USP/INN)
Tretinoin (TN)
Tretinoin 0.1% cream or placebo
Tretinoin Potassium Salt
Tretinoin Sodium Salt
Tretinoin Zinc Salt
Tretinoin [USAN:INN:BAN]
Tretinoin/All-Trans Retinoic Acid
Tretinoina
Tretinoina [INN-Spanish]
Tretinoine
Tretinoine (french) (einecs)
Tretinoine [INN-French]
Tretinoino
Tretinoino [INN-Spanish]
Tretinoinum
Tretinoinum [INN-Latin]
Tri-Luma
Trétinoïne
UNII-1UA8E65KDZ
UNII-5688UTC01R
UPCMLD-DP097
Vesanoid
Vesanoid (TN)
Vesanoid, Airol, Renova, Atralin, Retin-A, Avita, Tretinoin
Vesnaroid
Vitamin A acid
Vitinoin
WLN: L6UTJ A1 B1U1Y1 & U2U1Y1 & U1VQ C1 C1
WLN: L6UTJ A1 B1U1Y1&U2U1Y1&U1VQ C1 C1
Zinc Salt, Tretinoin
[3H]Retinoic acid
all trans-Retinoic acid
all-(E)-Retinoic acid
all-(e)-Retinoic acid
all-trans-Retinoic acid
all-trans-Tretinoin
all-trans-Vitamin A acid
all-trans-Vitamin A1 acid
all-trans-Vitamin a acid
all-trans-Vitamin a1 acid
all-trans-b-Retinoic acid
all-trans-beta-Retinoic acid
b-Retinoic acid
beta all trans Retinoic Acid
beta-Ra
beta-Retinoic Acid
beta-Retinoic acid
beta-all-trans-Retinoic acid
bmse000562
nchembio.154-comp2
trans Retinoic Acid
trans-Retinoic acid
tretinoin
tretinoin liposome
tretinoine (French) (EINECS)
35
MethylphenidatePhase 3369113-45-14158
Synonyms:
.alpha.-Phenyl-2-piperidineacetic acid methyl ester
113-45-1
2-Piperidineacetic acid, .alpha.-phenyl-, methyl ester
2-Piperidineacetic acid, alpha-phenyl-, methyl ester
298-59-9 (hydrochloride)
4311/B Ciba
AC1L1HJM
C 4311
C07196
CHEBI:6887
CHEMBL796
CID4158
Calocain
Centedein
Centedrin
Centedrine
Centredin
Concerta
D-Methylphenidate HCl
D04999
DB00422
DB06701
DEA No. 1724
Daytrana
Daytrana (TN)
EINECS 204-028-6
Focalin
Focalin XR
HSDB 3126
L001307
LS-565
METHYLPHENIDATE (SEE ALSO: METHYLPHENIDATE HYDROCHLORIDE, CAS 298-59-9, NTPNO 10266-R)
MPH
Meridil
Metadate
Metadate CD
Metadate ER
MethyPatch
Methyl (2-phenyl-2-(2-piperidyl)acetate)
Methyl alpha-phenyl-alpha-(2-piperidyl)acetate
Methyl alpha-phenyl-alpha-2-piperidinylacetate
Methyl phenidate
 
Methyl phenidyl acetate
Methyl phenidylacetate
Methylfenidan
Methylin
Methylin ER
Methylofenidan
Methylphen
Methylphenidan
Methylphenidate
Methylphenidate (USAN/INN)
Methylphenidate HCl
Methylphenidate [INN:BAN]
Methylphenidate hydrochloride
Methylphenidatum
Methylphenidatum [INN-Latin]
Methylphenidylacetate hydrochloride
Methypatch
Metilfenidat hydrochloride
Metilfenidato
Metilfenidato [INN-Spanish]
Metilfenidato [Italian]
MolPort-001-779-620
NCI-C56280
PMS-Methylphenidate
Phenidylate
Plimasine
Riphenidate
Ritalin
Ritalin LA
Ritalin SR
Ritalin hydrochloride
Ritalin-SR
Ritaline
Ritcher Works
Ritcher works
Tsentedrin
UNII-207ZZ9QZ49
alpha-Phenyl-2-piperidineacetic acid methyl ester
alpha-Phenyl-alpha-(2-piperidyl)acetic acid methyl ester
d-methylphenidate HCl
methyl 2-phenyl-2-piperidin-2-ylacetate
methyl phenyl(piperidin-2-yl)acetate
methylphenidate
nchembio.2007.55-comp28
36
MorphinePhase 391357-27-25288826
Synonyms:
(-)(5.alpha.,6.alpha.)-7,8-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
(-)-Heroin hydrochloride
(-)-Morphine
(-)Morphine sulfate
(5R,6S,9R,13S,14R)-4,5-Epoxy-N-methyl-7-morphinen-3,6-diol
(5alpha,6alpha)-17-Methyl-7,8-didehydro-4,5-epoxymorphinan-3,6-diol
(5alpha,6alpha)-17-methyl-7,8-didehydro-4,5-epoxymorphinan-3,6-diol
(5alpha,6alpha)-7,8-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
(5alpha,6alpha)-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
(7R,7AS,12BS)-3-METHYL-2,3,4,4A,7,7A-HEXAHYDRO-1H-4,12-METHANO[1]BENZOFURO[3,2-E]ISOQUINOLINE-7,9-DIOL
(7R,7AS,12bs)-3-methyl-2,3,4,4a,7,7a-hexahydro-1H-4,12-methano[1]benzofuro[3,2-e]isoquinoline-7,9-diol
(−)-morphine
17-methyl-7,8-didehydro-4,5alpha-epoxymorphinan-3,6alpha-diol
4,5alpha-Epoxy-17-methyl-7-morphinen-3,6alpha-diol
4-methyl-(13R,14S)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol
47106-99-0
57-27-2
6211-15-0 (sulfate (2:1) (salt) pentahydrate)
64-31-3
64-31-3 (sulfate (2:1) (salt) anhydrous)
7,8-Didehydro-4,5-epoxy-17-methyl-morphinan-3,6-diol
7,8-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
8053-16-5
85201-37-2
Apokyn
Astramorph PF
Avinza
BIDD:GT0147
C01516
CCRIS 5762
CHEBI:17303
CHEMBL70
CID5288826
Cube juice
D-(-)-Morphine
DB00295
DEA No. 9300
DepoDur
Depodur
Diacetylmorphine hydrochloride
Diamorphine hydrochloride
Dolcontin
Dreamer
Dulcontin
Duramorph PF
Duromorph
EINECS 200-320-2
Epimorph
HSDB 2134
Hard stuff
Heroin hydrochloride
Heroine hydrochloride
Hocus
Infumorph
Kadian
 
LS-91748
M-Eslon
M.O.S
MOI
MORPHINE SULFATE
MORPHINE, (5A,6A)-7,8-DIDEHYDRO-4,5-EPOXY-17-METHYLMORPHINIAN-3,6-DIOL, MORPHIUM, MORPHIA, DOLCONTIN, DUROMORPH, MORPHINA, NEPENTHE
MS Contin
MS/L
MS/S
MSIR
Meconium
MolPort-003-849-273
Morfina
Morfina [Italian]
Morphia
Morphin
Morphin [German]
Morphina
Morphina [Italian]
Morphine
Morphine Extra-Forte
Morphine Forte
Morphine H.P
Morphine Sulfate
Morphine [BAN]
Morphinism
Morphinum
Morphitec
Morphium
Morpho
Moscontin
Ms Contin
Ms Emma
NSC11441
Nepenthe
O,O'-Diacetylmorphine hydrochloride
OMS Concentrate
Oramorph SR
Ospalivina
RMS
RMS Uniserts
Rescudose
Roxanol
Roxanol 100
Roxanol UD
SDZ 202-250
SDZ202-250
Statex
Statex Drops
Statex SR
UNII-76I7G6D29C
Unkie
l-Morphine
morphine
nchembio.317-comp1
nchembio.64-comp1
37
ThiotepaPhase 2, Phase 3, Phase 121552-24-45453
Synonyms:
 
Thioplex
38Epoetin alfaPhase 3638113427-24-0
39pancreatic polypeptidePhase 3, Phase 120
40
VincristinePhase 3, Phase 2, Phase 18882068-78-2, 57-22-75978
Synonyms:
22-Oxovincaleukoblastin
22-Oxovincaleukoblastine
28379-27-3
57-22-7
AC1L1LJC
C07204
C46H56N4O10
CCRIS 5763
CHEBI:28445
CID5978
D08679
DB00541
EINECS 200-318-1
HMS2090E19
HSDB 3199
Indole alkaloid
LCR
LS-228
Leurocristine
Lilly 37231 (1:1 sulfate salt)
Liposomal Vincristine
Marqibo
NCGC00163700-01
NCI-C04864
NCI60_026703
NSC-67574
Onco TCS
 
Oncovin
Oncovin (1:1 sulfate salt)
Oncovine
Tecnocris
Tecnocris (TN)
UNII-5J49Q6B70F
VCR
VIN
Vincaleukoblastine, 22-oxo- 22-Oxovincaleukoblastine
Vincasar
Vincasar (1:1 sulfate salt)
Vincasar PFS
Vincrex
Vincrex (1:1 sulfate salt)
Vincristin
Vincristina
Vincristina [DCIT]
Vincristine (INN)
Vincristine Sulfate
Vincristine Sulfate PFS
Vincristine [INN:BAN]
Vincristinum
Vincristinum [INN-Latin]
Vincrstine
Vincrystine
Vinkristin
Z-D-Val-Lys(Z)-OH
vincristine
41
FentanylPhase 3739437-38-73345
Synonyms:
1-Phenethyl-4-(N-phenylpropionamido)piperidine
1-Phenethyl-4-N-propionylanilinopiperidine
437-38-7
5-22-08-00049 (Beilstein Handbook Reference)
80832-90-2
990-73-8 (citrate)
AC1L1FQ2
Actiq
BIDD:GT0555
BRN 0494484
CHEBI:119915
CHEMBL596
CID3345
D00320
DB00813
Duragesic
Duragesic (TN)
Duragesic-100
Duragesic-12
Duragesic-25
Duragesic-50
Duragesic-75
Durogesic
EINECS 207-113-6
Fentanest
Fentanil
Fentanil [DCIT]
Fentanila
Fentanila [INN-Spanish]
Fentanilo
Fentanyl
Fentanyl (JAN/USAN/INN)
Fentanyl [INN:BAN]
Fentanyl citrate
Fentanyl-100
 
Fentanyl-12
Fentanyl-25
Fentanyl-50
Fentanyl-75
Fentanylum
Fentanylum [INN-Latin]
HSDB 3329
IONSYS
JNS020QD
L001275
LS-124439
Matrifen
MolPort-003-847-369
N-(1-Phenethyl-4-piperidinyl)-N-phenylpropionamide
N-(1-Phenethyl-4-piperidyl)propionanilide
N-(1-Phenethyl-piperidin-4-yl)-N-phenyl-propionamide
N-(1-Phenethylpiperidin-4-yl)-N-phenylpropionamide
N-(1-phenethylpiperidin-4-yl)-N-phenylpropanamide
N-Phenethyl-4-(N-propionylanilino)piperidine
N-Phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)propanamide
N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide
NCGC00168252-01
Nasalfent
Oprea1_152073
Oprea1_207148
PDSP1_000860
PDSP2_000846
Pentanyl
Phentanyl
Propanamide, N-phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)- (9CI)
R 4263
Rapinyl
Sentonil
Sublimase
Sublimaze
UNII-UF599785JZ
fentanyl
42
nivolumabPhase 3, Phase 2, Phase 1254946414-94-4
Synonyms:
BMS-936558
 
MDX-1106
ONO-4538
nivolumab
43
DopaminePhase 3, Phase 1, Phase 2367851-61-6, 62-31-7681
Synonyms:
(3H)-Dopamine
.Beta.-(3,4-Dihydroxyphenyl)ethylamine hydrochloride
.alpha.-(3,4-Dihydroxyphenyl)-.beta.-aminoethane
1,2-Benzenediol, 4-(2-aminoethyl)- (9CI)
1,2-Benzenediol, 4-(2-aminoethyl)-, hydrochloride
1,2-Benzenediol, 4-(2-aminoethyl)-, labeled with tritium
153C5321-5FEE-4B0B-8925-F388F0EEEBD1
2-(3,4-Dihydroxyphenyl)ethylamine
2-(3,4-dihydroxyphenyl)ethylamine
2-benzenediol
3,4-Dihydroxyphenethylamine
3,4-Dihydroxyphenethylamine hydrochloride
3,4-Dihydroxyphenylethylamine
3,4-dihydroxyphenethylamine
3-Hydroxtyramine
3-Hydroxytyramine
3-Hydroxytyramine Hydrobromide
3-Hydroxytyramine hydrochloride
4-(2-Aminoethyl)-1,
4-(2-Aminoethyl)-1,2-benzenediol
4-(2-Aminoethyl)-1,2-bezenediol
4-(2-Aminoethyl)-Pyrocatechol
4-(2-Aminoethyl)benzene-1,2-diol
4-(2-Aminoethyl)catechol
4-(2-Aminoethyl)pyrocatechol
4-(2-Aminoethyl)pyrocatechol hydrochloride
4-(2-aminoethyl)-pyrocatechol
50444-17-2
51-61-6
62-31-7 (HYDROCHLORIDE)
AC1L19S5
AC1Q54AX
AC1Q54AY
AKOS003790978
ASL 279
BIDD:ER0506
BPBio1_001123
BSPBio_001932
Biomol-NT_000001
C03758
CHEBI:18243
CHEMBL59
CID681
D07870
DB00988
Deoxyepinephrine
DivK1c_000780
Dopamin
Dopamina
Dopamina [INN-Spanish]
Dopamine
Dopamine (INN)
Dopamine (USAN)(*hydrochloride*)
Dopamine [INN:BAN]
Dopaminum
Dopaminum [INN-Latin]
Dopastat
Dophamine
Dynatra
EINECS 200-110-0
HSDB 3068
Hydroxytyramin
Hydroxytyramine
IDI1_000780
IP 498
Intropin
Intropin [*hydrochloride*]
KBio1_000780
 
KBio2_001492
KBio2_002388
KBio2_002484
KBio2_004060
KBio2_004956
KBio2_005052
KBio2_006628
KBio2_007524
KBio2_007620
KBio3_001152
KBio3_002867
KBio3_002962
KBioGR_001129
KBioGR_002388
KBioGR_002484
KBioSS_001492
KBioSS_002393
KBioSS_002491
KW-3-060
L-DOPAMINE
L000232
LDP
LS-159
Lopac-H-8502
Lopac0_000586
Medopa (TN)
MolPort-001-641-000
NCGC00015519-01
NCGC00015519-08
NCGC00096050-01
NCGC00096050-02
NCGC00096050-03
NCGC00096050-04
NCGC00096050-05
NINDS_000780
NSC 173182
NSC169105
NSC173182
Oprea1_088821
Oxytyramine
Pyrocatechol, 4-(2-aminoethyl)- (8CI)
Pyrocatechol, 4-(2-aminoethyl)-, hydrochloride
Revimine
Revivan
SPBio_001205
SPECTRUM1505155
ST048774
STK301601
Spectrum2_001023
Spectrum3_000406
Spectrum4_000525
Spectrum5_000945
Spectrum_001012
UNII-VTD58H1Z2X
UPCMLD0ENAT5885989:001
a-(3,4-Dihydroxyphenyl)-b-aminoethane
alpha-(3,4-Dihydroxyphenyl)-beta-aminoethane
cMAP_000036
cMAP_000065
dopamine
hydroxytyramine
intropin
m-Hydroxytyramine hydrochloride
nchembio.105-comp9
nchembio.107-comp4
nchembio.284-comp1
nchembio.78-comp16
nchembio.89-comp3
nchembio705-8
nchembio801-comp8
44
Histamine PhosphatePhase 3, Phase 2100851-74-165513
Synonyms:
1H-Imidazole-4-ethanamine, phosphate (1:2)
2-Imidazol-4-ylethylamine orthophosphoric acid (1:2)
4-(2-Aminoethyl)imidazole bis(dihydrogen phosphate)
4-(2-Aminoethyl)imidazole di-acid phosphate
4-2(2-Aminoethyl)Imidazole-Di-Acid Phosphate
51-74-1
53623-99-7
74-56-6
AC1L23E4
CID65513
D04445
DB00667
 
EINECS 200-118-4
H0147
Histamine acid phosphate
Histamine biphosphate
Histamine dihydrogen phosphate
Histamine diphosphate
Histamine phosphate (1:2)
Histamine phosphate (TN)
Histamine phosphate (USP)
Histamine phosphate [USP]
Histamine positive
Histaminum
LS-78569
UNII-QWB37T4WZZ
45
histaminePhase 3, Phase 2100975614-87-8, 51-45-6774
Synonyms:
.beta.-Imidazolyl-4-ethylamine
1H-Imidazole-4-ethanamine
1H-Imidazole-5-ethanamine
1avn
1qft
2-(1H-Imidazol-4-yl)ethanamine
2-(1H-Imidazol-4-yl)ethylamine
2-(1H-Imidazol-5-yl)ethanamine
2-(1H-Imidazol-5-yl)ethylamine
2-(1H-imidazol-4-yl)ethan-1-amine
2-(1H-imidazol-5-yl)ethanamine
2-(3H-Imidazol-4-yl)-ethylamine
2-(4-Imidazolyl)ethanamine
2-(4-Imidazolyl)ethylamine
2-Imidazol-4-yl-Ethylamine
2-Imidazol-4-ylethylamine
2-[4-Imidazolyl]ethylamine
4-(2-Aminoethyl)-1H-imidazole
4-(2-Aminoethyl)imidazole
4-Imidazoleethylamine
5-Imidazoleethylamine
51-45-6
53290_FLUKA
64422-25-9
924364-91-0
AC-13185
AC1L19ZT
AC1Q54BV
AC1Q54BW
AKOS000274386
ALBB-005968
BCBcMAP01_000250
BSPBio_001117
BSPBio_002124
Bio1_000487
Bio1_000976
Bio1_001465
Bio2_000389
Bio2_000869
C00388
CCRIS 6535
CHEBI:18295
CHEMBL90
CID774
D08040
DivK1c_000308
EINECS 200-100-6
Eramin
Ergamine
Ergotidine
F411C768-A159-4FC0-A195-291A08BB03AA
Free histamine
H7125_SIGMA
HMS1362G19
HMS1792G19
HMS1990G19
HSDB 3338
HSM
Histamine
Histamine (DCF)
Histamine Base
Histamine [USAN]
Histamine, Free Base
Histaminum
 
Histaminum (TN)
IDI1_000308
IDI1_002144
Imidazole-4-ethylamine
Istamina
Istamina [Italian]
KBio1_000308
KBio2_000457
KBio2_001325
KBio2_003025
KBio2_003893
KBio2_005593
KBio2_006461
KBio3_000853
KBio3_000854
KBio3_001344
KBioGR_000457
KBioGR_001580
KBioSS_000457
KBioSS_001325
L-Histamin base
L-Histamine
L-histamine
L000292
LS-75835
Lopac-H-7250
Lopac0_000595
MLS000069447
MolPort-001-785-597
MolPort-002-042-264
NCGC00015513-01
NCGC00015513-08
NCGC00093371-02
NCGC00093371-03
NCGC00093371-04
NCGC00093371-05
NINDS_000308
NSC 33792
NSC33792
SDCCGMLS-0066601.P001
SMP1_000151
SMR000059091
SPBio_000729
ST073926
STK346752
STOCK5S-55669
Spectrum2_000665
Spectrum3_000452
Spectrum4_000960
Spectrum5_000796
Spectrum_000845
Theramine
UNII-820484N8I3
WLN: T5M CNJ D2Z
ZERO/004089
[3H]histamine
b-Imidazolyl-4-ethylamine
beta-Aminoethylglyoxaline
beta-Aminoethylimidazole
beta-Aminothethylglyoxaline
beta-Imidazolyl-4-ethylamine
beta-aminothethylglyoxaline
bmse000744
histamine
nchembio.87-comp54
nchembio714-comp1
46
angiotensin IIPhase 3113568521-88-0, 11128-99-7172198, 65143
Synonyms:
1-8-Angiotensin I
1-L-Aspasaginyl-5-L-valyl angiotensin octapeptide
Ang II
Angiotensin 2
Angiotensin II (human)
 
Angiotensin II (mouse)
Angiotonin
Asp-arg-val-TYR-ile-his-pro-phe
Human angiotensin II
Hypertensin
Ile(5)-angiotensin II
47
LosartanPhase 3281114798-26-43961
Synonyms:
(2-Butyl-4-chloro-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-imidazol-5-yl)methanol
(2-butyl-4-chloro-1-{[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl}-1H-imidazol-5-yl)methanol
(2-butyl-4-chloro-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-imidazol-5-yl)methanol
114798-26-4
124750-99-8 (mono-potassium salt)
1H-Imidazole-5-methanol, 2-butyl-4-chloro-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]- (9CI)
2-Butyl-4-chloro-1-((2'-(1H-etrazol-5-yl) (1,1'-biphenyl)-4-yl)methyl)-1H-imidazole-5-methanol
2-Butyl-4-chloro-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl-1H-imidazole-5-methanol
2-N-Butyl-4-chloro-5-hydroxymethyl-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]imidazole
2-butyl-4-chloro-1-[p-(o-1H-tetrazol-5ylphenyl)benzyl]imidazole-5-methanol
2-n-butyl-4-chloro-5-hydroxymethyl-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]imidazole
2-n-butyl-4-chloro-5-hydroxymethyl-1-[[2'-(1H-tetrazol-5-yl)-biphenyl-4-yl]methyl]imidazole
AC1L1H3Q
BIDD:GT0286
BRD-K76205745-001-02-5
BSPBio_002695
C07072
C22H23ClN6O
CHEBI:6541
CHEMBL191
CID3961
CL23623
Cozaar
D08146
DB00678
DUP 89
DuP 89
DuP-753
HMS1922J13
HMS2093E22
Hyzaar
I14-9710
Jsp001094
KBio2_002193
 
KBio2_004761
KBio2_007329
KBio3_001915
KBioGR_001611
KBioSS_002193
L000351
LOSARTAN POTASSIUM
LS-78746
Lacidipine
Lortaan
Losartan
Losartan (INN)
Losartan Potassium
Losartan [INN:BAN]
Losartan monopotassium salt
Losartic
Losartic (TN)
MK-954
MK954
MolPort-003-666-553
NCGC00095125-01
NCGC00095125-02
NCGC00095125-03
Oprea1_644635
SPBio_001893
SPECTRUM1504268
Spectrum2_001677
Spectrum3_000998
Spectrum4_001126
Spectrum5_001466
Spectrum_001713
UNII-JMS50MPO89
[2-butyl-5-chloro-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol
losartan
losartan potassium
48
MelphalanPhase 2, Phase 3697148-82-34053, 460612
Synonyms:
(2S)-2-amino-3-[4-[bis(2-chloroethyl)amino]phenyl]propanoic acid
(2s)-2-amino-3-(4-[bis(2-chloroethyl)amino]phenyl)propanoic acid
148-82-3
3-(P-(Bis(2-chloroethyl)amino)phenyl)-L-alanine
3-(p-(Bis(2-chloroethyl)amino)phenyl)-L-alanine
3-(p-(Bis(2-chloroethyl)amino)phenyl)alanine
3-P-(Di(2-chloroethyl)amino)-phenyl-L-alanine
3-p-(Di(2-chloroethyl)amino)-phenyl-L-alanine
3025 C.B.
3025 c.b
3223-07-2
4-(Bis(2-chloroethyl)amino)-L-phenylalanine
4-14-00-01689 (Beilstein Handbook Reference)
4-[Bis(2-chloroethyl)amino]-L-phenylalanine
4-[Bis-(2-chloroethyl)amino]-L-phenylalanine
AC1LA2OE
ALKERAN (TN)
AY3360000
Alanine Nitrogen Mustard
Alkeran
AmbotzHAA1563
At-290
BIDD:GT0044
BRD-K87827419-001-02-8
BRN 2816456
BSPBio_002407
C13H18Cl2N2O2
CB 3025
CB-3025
CCRIS 374
CHEBI:165415
CHEBI:28876
CHEMBL852
CID460612
D00369
DivK1c_000653
EINECS 205-726-3
HMS2090B09
HMS2091B16
HMS502A15
HSDB 3234
IDI1_000653
KBio1_000653
KBio2_000877
KBio2_003445
KBio2_006013
KBio3_001627
KBioGR_001284
KBioSS_000877
L-3-(P-(Bis(2-chloroethyl)amino)phenyl)alanine
L-3-(p-(Bis(2-chloroethyl)amino)phenyl)alanine
L-3-(para-(Bis(2-chloroethyl)amino)phenyl)alanine
L-PAM
L-Phenylalanine mustard
L-Sarcolysin
L-Sarcolysine
L-Sarkolysin
LS-15868
LS-865
 
Levofalan
Levofolan
Levopholan
M2011_SIGMA
MELPHALAN (SEE ALSO TRANSGENIC MODEL EVALUATION (MELPHALAN))
MLS001333666
MLS002153368
Melfalan
Melfalano
Melfalano [INN-Spanish]
Melphalan (JP15/USP/INN)
Melphalan [USAN:INN:BAN:JAN]
Melphalanum
Melphalanum [INN-Latin]
Mephalan
MolPort-003-665-535
NCGC00090757-01
NCGC00090757-02
NCGC00090757-03
NCI-C04853
NINDS_000653
NIOSH/AY3360000
NSC 241286
NSC 8806
NSC-8806
NSC241286
NSC8806
P-Di-(2-chloroethyl)amino-L-phenylalanine
P-L-Sarcolysin
P-N-Bis(2-chloroethyl)amino-L-phenylalanine
Phenylalanine mustard
Phenylalanine nitrogen mustard
Prestwick_1006
RCRA waste no. U150
Rcra waste number U150
SK-15673
SMP2_000174
SMR000058720
SPBio_000287
SPECTRUM1500382
Sarcolysine
Sarkolysin
Spectrum2_000074
Spectrum3_000684
Spectrum4_000882
Spectrum5_001601
Spectrum_000397
TL8001065
TRANSGENIC LEP (MELPHALAN) (SEE ALSO MELPHALAN)
TRANSGENIC MODEL EVALUATION (MELPHALAN)
UNII-Q41OR9510P
melphalan
p-Bis(beta-chloroethyl)aminophenylalanine
p-Di-(2-chloroethyl)amino-L-phenylalanine
p-L-Sarcolysin
p-L-sarcolysine
p-N,N-bis(2-chloroethyl)amino-L-phenylalanine
p-N-Bis(2-chloroethyl)amino-L-phenylalanine
p-N-Di(chloroethyl)aminophenylalanine
p-N-di(chloroethyl)aminophenylala nine
phenylalanine nitrogen mu stard
49
MeloxicamPhase 2, Phase 37571125-38-75281106, 54677470
Synonyms:
(3E)-3-[hydroxy-[(5-methyl-1,3-thiazol-2-yl)amino]methylidene]-2-methyl-1,1-dioxo-1
133687-22-6
2H-1,2-Benzothiazine-3-carboxamide, 4-hydroxy-2-methyl-N-(5-methylthiazolyl)-, 1,1-dioxide
4-Hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide
4-Hydroxy-2-methyl-N-(5-methyl-2-thiazoyl)-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxide
4-hydroxy-2-mehtyl-N-(5-mehtyl-2-thiazolyl)-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide
4-hydroxy-2-methyl-N-(5-methyl-1,3-thiazol-2-yl)-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide
4-hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxide
71125-38-7
AC-1325
AC1NQY12
AC1Q3XZW
AKOS000279442
Abbott brand of meloxicam
Almirall brand of meloxicam
Apo-meloxicam
Bio-0826
Boehringer Ingelheim brand of meloxicam
C065757
C08169
C14H13N3O4S2
CCRIS 9139
CHEMBL599
CID5281106
Co Meloxicam
D00969
DB00814
Dom-meloxicam
Europharma brand of meloxicam
FT-0082769
Gen-meloxicam
HMS1922D19
HMS2089B18
I06-0490
LS-40538
M1959
Masflex
 
Meloxicam
Meloxicam (JAN/USAN/INN)
Meloxicam [USAN:BAN:INN]
Meloxicamum
Meloxicamum [Latin]
Meloxicamum [latin]
Meloxivet
Metacam
Mobec
Mobic
Mobic (TN)
Mobic, Metacam, Parocin, Meloxicam
Mobicox
MolPort-002-885-839
Movalis
Movatec
Movicox
Méloxicam
Novo-meloxicam
PHL-meloxicam
PMS-meloxicam
Parocin
Promeco brand of meloxicam
Ratio-meloxicam
S1734_Selleck
SPECTRUM1504150
STK620505
Squibb brand of meloxicam
TL8005001
Tenaron
UH-AC 62XX
UHAC-62XX
UNII-VG2QF83CGL
UNII-vg2qf83cgl
Uticox
meloxicam
miloxicam
reumoxicam
50
SerotoninPhase 2, Phase 3, Phase 1351050-67-95202
Synonyms:
3-(2-Aminoethyl)-1H-indol-5-ol
3-(2-Aminoethyl)indol-5-ol
3-(b-Aminoethyl)-5-hydroxyindole
5-HT
5-HTA
5-Hydroxy-3-(b-aminoethyl)indole
 
5-Hydroxy-tryptamine
5-Hydroxyltryptamine
5-Hydroxytriptamine
5-Hydroxytryptamine
Antemovis
DS substance
Enteramin
Enteramine

Interventional clinical trials:

(show top 50)    (show all 1138)
idNameStatusNCT IDPhase
1Standard Temodal (Temozolomide) Regimen Versus Standard Regimen Plus Early Postsurgery Temodal for Newly Diagnosed Glioblastoma Multiforme (Study P05572)CompletedNCT00686725Phase 4
2Supra-early Post-Surgery Chemotherapy in the Treatment on GBM PatientsRecruitingNCT02520635Phase 4
3Post-approval Study of NovoTTF-100A in Recurrent GBM PatientsTerminatedNCT01756729Phase 4
4The PRECISE Trial: Study of IL13-PE38QQR Compared to GLIADEL Wafer in Patients With Recurrent Glioblastoma MultiformeCompletedNCT00076986Phase 3
5Chloroquine for Treatment of Glioblastoma MultiformeCompletedNCT00224978Phase 3
6Short Course vs. Standard Course Radiotherapy in Elderly and/or Frail Patients With Glioblastoma MultiformeCompletedNCT01450449Phase 3
7Study of Imatinib Mesylate in Combination With Hydroxyurea Versus Hydroxyurea Alone as an Oral Therapy in Patients With Temozolomide Resistant Progressive GlioblastomaCompletedNCT00154375Phase 3
8SU-101 Compared With Procarbazine in Treating Patients With Glioblastoma MultiformeCompletedNCT00003293Phase 3
9Radiation Therapy With or Without Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma MultiformeCompletedNCT00006353Phase 3
10Radiation Therapy With or Without Temozolomide in Treating Older Patients With Newly Diagnosed Glioblastoma MultiformeCompletedNCT00482677Phase 3
11Study of IV Edotecarin Vs Temozolomide or Carmustine (BCNU) or Lomustine (CCNU) in Patients With Glioblastoma MultiformeCompletedNCT00068952Phase 3
12Nimotuzumab in Adults With Glioblastoma MultiformaCompletedNCT00753246Phase 3
13Radiation Therapy Plus Chemotherapy in Treating Patients With Supratentorial Glioblastoma MultiformeCompletedNCT00002545Phase 3
14Enzastaurin Versus Lomustine in GlioblastomaCompletedNCT00295815Phase 3
15S0001 RT and Carmustine With or Without O6BG in Patients With New Glioblastoma Multiforme or GliosarcomaCompletedNCT00017147Phase 3
16Effect of NovoTTF-100A in Recurrent Glioblastoma Multiforme (GBM)CompletedNCT00379470Phase 3
17Clinical Trial to Assess the Efficacy and Safety of 'INNOCELL Immuncell-LC' With Temozolomide in Newly Diagnosed Glioblastoma of KoreaCompletedNCT00807027Phase 3
18Comparison of TransMID vs Standard Treatment of Cancerous Brain TumorsCompletedNCT00088400Phase 3
19Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Methylated Gene Promoter StatusCompletedNCT00689221Phase 3
20Efficacy and Safety of Temodal vs Semustine in Subjects With Recurrent Glioblastoma or Anaplastic Astrocytoma (Study P03644)CompletedNCT00335075Phase 3
21Conventional Adjuvant Temozolomide With Dose Intensive Temozolomide in Patients With Newly Diagnosed GlioblastomaCompletedNCT01364064Phase 3
22Standard Radiation Therapy, Higher-Dose Radiation Therapy, or Chemotherapy in Treating Older Patients With Glioblastoma MultiformeCompletedNCT00820963Phase 3
23Radiotherapy for Malignant Astrocytomas in the ElderlyCompletedNCT00430911Phase 3
24A Study of Avastin® (Bevacizumab) in Combination With Temozolomide and Radiotherapy in Patients With Newly Diagnosed GlioblastomaCompletedNCT00943826Phase 3
25Phase III Trial of Primary Radio- or Chemotherapy in Malignant Astrocytoma of the ElderlyCompletedNCT01502241Phase 3
26Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer PainCompletedNCT00538850Phase 3
27E-MOSAIC Electronic Tool to Monitor SymptomsCompletedNCT00477919Phase 3
28Donepezil in Treating Patients Who Have Undergone Radiation Therapy for Brain TumorsCompletedNCT00369785Phase 3
29Temozolomide Compared to Procarbazine, Lomustine, and Vincristine in Treating Patients With Recurrent Malignant GliomaCompletedNCT00052455Phase 3
30Standard Radiation Therapy With or Without Stereotactic Radiation Therapy in Treating Patients With GliomaCompletedNCT00003916Phase 3
31High Light and Low Light Dose PDT in GliomaCompletedNCT00118222Phase 3
32Intraoperative Radiotherapy in Newly Diagnosed Glioblastoma MultiformeRecruitingNCT02685605Phase 3
33Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma MultiformeRecruitingNCT02152982Phase 2, Phase 3
34Phase III Study Comparing 2 Brain Conformational Radiotherapy in Combination With Chemotherapy in the Treatment of GlioblastomaRecruitingNCT01507506Phase 3
35Phase 3 Randomized, Double-blind, Controlled Study of ICT-107 in GlioblastomaRecruitingNCT02546102Phase 3
36Bevacizumab Alone Versus Dose-dense Temozolomide Followed by Bevacizumab for Recurrent Glioblastoma, Phase IIIRecruitingNCT02761070Phase 3
37A Phase 3, Pivotal Trial of VB-111 Plus Bevacizumab vs. Bevacizumab in Patients With Recurrent Glioblastoma (GLOBE)RecruitingNCT02511405Phase 3
38A Study of the Effectiveness and Safety of Nivolumab Compared to Bevacizumab and of Nivolumab With or Without Ipilimumab in Glioblastoma PatientsRecruitingNCT02017717Phase 3
39Study of Nivolumab Compared to Temozolomide, Given With Radiation Therapy, for Newly-diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer)RecruitingNCT02617589Phase 3
40P2/3 Randomized Study of Toca 511 & Toca FC Versus SOC in Subjects Undergoing Surgery for Recurrent GBM/AARecruitingNCT02414165Phase 2, Phase 3
41A Study on β-elemene as Maintain Treatment for Complete Remission Patients of Newly Diagnosed Malignant Gliomas Following Standard TreatmentRecruitingNCT02629757Phase 3
42A Phase III Trial on Adjuvant Temozolomide With or Without Interferon-alpha in Newly Diagnosed High-grade GliomasRecruitingNCT01765088Phase 3
43Impact of Surgery on the Treatment of Supratentorial Malignant Gliomas in Subjects Aged 70 and OverRecruitingNCT02892708Phase 3
44Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed GlioblastomaActive, not recruitingNCT01480479Phase 3
45Effect of NovoTTF-100A Together With Temozolomide in Newly Diagnosed Glioblastoma Multiforme (GBM)Active, not recruitingNCT00916409Phase 3
46Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain CancerActive, not recruitingNCT00045968Phase 3
47Angiotensin II Receptor Blockers, Steroids and Radiotherapy in GlioblastomaActive, not recruitingNCT01805453Phase 3
48Metronomic Temozolamide in Patients With Recurrent GlioblastomaActive, not recruitingNCT01308632Phase 2, Phase 3
49Cediranib in Combination With Lomustine Chemotherapy in Recurrent GlioblastomaActive, not recruitingNCT00777153Phase 3
50Bevacizumab and Lomustine for Recurrent GBMActive, not recruitingNCT01290939Phase 3

Search NIH Clinical Center for Glioblastoma Multiforme

Inferred drug relations via UMLS66/NDF-RT44:


Cochrane evidence based reviews: glioblastoma

Genetic Tests for Glioblastoma Multiforme

About this section

Anatomical Context for Glioblastoma Multiforme

About this section

MalaCards organs/tissues related to Glioblastoma Multiforme:

34
Brain, T cells, Endothelial, Bone, Bone marrow, Testes, Prostate

Animal Models for Glioblastoma Multiforme or affiliated genes

About this section

MGI Mouse Phenotypes related to Glioblastoma Multiforme:

39 (show all 39)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053889.8AKT1, CDKN2A, EGFR, IDH1, MTOR, PDGFRA
2MP:00053829.8EGFR, GSK3B, MDM2, MYC, PDGFRA, PDGFRB
3MP:00053759.8AKT1, EGFR, MTOR, MYC, PDGFRB, PTEN
4MP:00011869.7CDK4, CDKN2A, EGFR, GPNMB, MDM2, MYC
5MP:00053719.6EGFR, MDM2, MYC, PDGFRA, PDGFRB, PTEN
6MP:00030129.5CDKN2A, EGFR, GSK3B, MDM2, MGMT, MTOR
7MP:00053919.3CDK2, CDK4, CDKN2A, EGF, EGFR, GPNMB
8MP:00053709.1AKT1, CDK2, CDK4, CDK6, CDKN2A, EGFR
9MP:00053679.1CDK4, DMBT1, EGFR, GSK3B, MDM2, MTOR
10MP:00107719.1AKT1, CDK2, CDK4, CDKN2A, EGF, EGFR
11MP:00053869.0AKT1, AKT3, CDK4, CDKN2A, GSK3B, MDM2
12MP:00053698.8AKT1, CDK2, CDK4, CDK6, CDKN2A, EGFR
13MP:00053818.8CDK4, CDKN2A, DMBT1, EGF, EGFR, GSK3B
14MP:00053908.7AKT1, CDKN2A, EGFR, GSK3B, IDH1, MDM2
15MP:00028738.6AKT1, AKT3, CDK4, EGF, EGFR, GSK3B
16MP:00053808.6AKT1, CDK2, CDK4, CDK6, CDKN2A, DMBT1
17MP:00053898.6AKT1, AKT3, CDK2, CDK4, CDK6, CDKN2A
18MP:00020068.5AKT1, AKT3, CDK2, CDK4, CDK6, CDKN2A
19MP:00036318.5AKT1, AKT3, CDK4, CDKN2A, EGFR, GPNMB
20MP:00053848.5AKT1, AKT3, CDK2, CDK4, CDK6, CDKN2A
21MP:00053978.5AKT1, AKT3, CDK2, CDK4, CDK6, CDKN2A
22MP:00053858.4AKT1, AKT3, CDK2, CDK4, CDK6, CDKN2A
23MP:00053797.9AKT1, AKT3, CDK2, CDK4, CDK6, CDKN2A
24MP:00053787.9AKT1, AKT3, CDK2, CDK4, CDK6, CDKN2A
25MP:00053767.8AKT1, AKT3, CDK2, CDK4, CDKN2A, DMBT1
26MP:00107687.8AKT1, AKT3, CDK2, CDK4, CDK6, CDKN2A
27MP:00053877.8AKT1, AKT3, CDK2, CDK4, CDK6, CDKN2A

Publications for Glioblastoma Multiforme

About this section

Articles related to Glioblastoma Multiforme:

(show top 50)    (show all 748)
idTitleAuthorsYear
1
Prognostic value of relative cerebral blood volume (rCBV) in patients with recurrent glioblastoma multiforme treated with bevacizumab. (27603407)
2016
2
High metallothionein predicts poor survival in glioblastoma multiforme. (26493598)
2015
3
SREBP maintains lipid biosynthesis and viability of cancer cells under lipid- and oxygen-deprived conditions and defines a gene signature associated with poor survival in glioblastoma multiforme. (25619842)
2015
4
Combined inhibition of AKT/mTOR and MDM2 enhances Glioblastoma Multiforme cell apoptosis and differentiation of cancer stem cells. (25898313)
2015
5
Differentiation of solitary brain metastasis from glioblastoma multiforme: a predictive multiparametric approach using combined MR diffusion and perfusion. (25845813)
2015
6
Genetic investigation of multicentric glioblastoma multiforme: case report. (26473785)
2015
7
Knockdown of the AKT3 (PKBI^), PI3KCA, and VEGFR2 genes by RNA interference suppresses glioblastoma multiforme T98G cells invasiveness in vitro. (25501707)
2015
8
Dendritic cell vaccination combined with temozolomide retreatment: results of a phase I trial in patients with recurrent glioblastoma multiforme. (25366363)
2014
9
Vitamin D receptor expression is associated with improved overall survival in human glioblastoma multiforme. (24584679)
2014
10
The contrasting epigenetic role of RUNX3 when compared with that of MGMT and TIMP3 in glioblastoma multiforme clinical outcomes. (25467143)
2014
11
Haematological toxicity of Valproic acid compared to Levetiracetam in patients with glioblastoma multiforme undergoing concomitant radio-chemotherapy: a retrospective cohort study. (25359262)
2014
12
Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multiforme after BRAF inhibitor therapy. (24725538)
2014
13
Raman spectroscopy to distinguish grey matter, necrosis, and glioblastoma multiforme in frozen tissue sections. (24390405)
2014
14
Case Report: Glioblastoma Multiforme Complicating Familial Cavernous Malformations. (23942770)
2013
15
Dioscin, a natural steroid saponin, induces apoptosis and DNA damage through reactive oxygen species: a potential new drug for treatment of glioblastoma multiforme. (23871826)
2013
16
Role of moesin in hyaluronan induced cell migration in glioblastoma multiforme. (23855374)
2013
17
Human cytomegalovirus infection levels in glioblastoma multiforme are of prognostic value for survival. (23391370)
2013
18
Meningeal seeding from glioblastoma multiforme treated with radiotherapy andA temozolomide. (23978432)
2013
19
Temozolomide and Radiotherapy for Newly Diagnosed Glioblastoma Multiforme: A Systematic Review. (24328555)
2013
20
Targeted induction of apoptosis in glioblastoma multiforme cells by an MRP3-specific TRAIL fusion protein in vitro. (24272336)
2013
21
Differential expression of HIF-1 in glioblastoma multiforme and anaplastic astrocytoma. (22825389)
2012
22
Overexpression of Golgi phosphoprotein-3 (GOLPH3) in glioblastoma multiforme is associated with worse prognosis. (22972189)
2012
23
TLR9 expression is associated with prognosis in patients with glioblastoma multiforme. (22169598)
2012
24
Search for a diagnostic/prognostic biomarker for the brain cancer glioblastoma multiforme by 2D-DIGE-MS technique. (22547198)
2012
25
Deciphering the signaling pathways of cancer stem cells of glioblastoma multiforme: role of Akt/mTOR and MAPK pathways. (21035497)
2011
26
Danthron induced apoptosis through mitochondria- and caspase-3-dependent pathways in human brain glioblastoma multiforms GBM 8401 cells. (19784869)
2010
27
Implication of 5-aminolevulinic acid fluorescence of the ventricular wall for postoperative communicating hydrocephalus associated with cerebrospinal fluid dissemination in patients with glioblastoma multiforme: a report of 7 cases. (19747042)
2010
28
Stem cell associated gene expression in glioblastoma multiforme: relationship to survival and the subventricular zone. (19655089)
2010
29
Bevacizumab and irinotecan therapy in glioblastoma multiforme: a series of 13 cases. (18671639)
2008
30
Mutational inactivation of PTPRD in glioblastoma multiforme and malignant melanoma. (19074898)
2008
31
Long-term survival with glioblastoma multiforme. (17785346)
2007
32
Hypermethylation of the proapoptotic gene TMS1/ASC: prognostic importance in glioblastoma multiforme. (17048097)
2007
33
Nestin expression in the cell lines derived from glioblastoma multiforme. (16457706)
2006
34
Multicentric glioblastoma multiforme in a patient with BRCA-1 invasive breast cancer. (16958968)
2006
35
Malignant optic nerve glioma (glioblastoma multiforme): A case report and literature review. (17111679)
2006
36
Treatment of primary glioblastoma multiforme with cetuximab, radiotherapy and temozolomide (GERT)--phase I/II trial: study protocol. (16709245)
2006
37
PI3K-AKT pathway negatively controls EGFR-dependent DNA-binding activity of Stat3 in glioblastoma multiforme cells. (16007122)
2005
38
Extra-cranial metastasis of glioblastoma multiforme presenting as acute parotitis. (16455543)
2005
39
Gene amplification and splice variants of 25-hydroxyvitamin D3 1,alpha-hydroxylase (CYP27B1) in glioblastoma multiforme--a possible role in tumor progression? (12899520)
2003
40
Inhibition of constitutively active Stat3 suppresses proliferation and induces apoptosis in glioblastoma multiforme cells. (12466961)
2002
41
Association of elevated glial expression of interleukin-1beta with improved survival in patients with glioblastomas multiforme. (11838804)
2002
42
Glioblastoma multiforme of the brain stem in a patient with acquired immunodeficiency syndrome. (12376778)
2002
43
Activity of glycogen depolymerizing enzymes in extracts from brain tumor tissue (anaplastic astrocytoma and glioblastoma multiforme). (11995970)
2001
44
Small cell architecture--a histological equivalent of EGFR amplification in glioblastoma multiforme? (11706939)
2001
45
Actinomycin D and staurosporine, potent apoptosis inducers in vitro, are potentially effective chemotherapeutic agents against glioblastoma multiforme. (10663630)
2000
46
Expression of p19INK4d, CDK4, CDK6 in glioblastoma multiforme. (10884881)
2000
47
Structure of the human allelic glutathione S-transferase-pi gene variant, hGSTP1 C, cloned from a glioblastoma multiforme cell line. (9679546)
1998
48
Role of CD44 in the invasiveness of glioblastoma multiforme and the noninvasiveness of meningioma: an immunohistochemistry study. (7557949)
1995
49
Ras p21 expression in brain tumors: elevated expression in malignant astrocytomas and glioblastomas multiforme. (1667267)
1991
50
Gliomatosis cerebri with formation of a glioblastoma multiform. Study and follow-up by magnetic resonance and computed tomography. (2848658)
1988

Variations for Glioblastoma Multiforme

About this section

Copy number variations for Glioblastoma Multiforme from CNVD:

6 (show top 50)    (show all 760)
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
11331511117600000GainGlioblastoma multiforme
21333311124300000GainGlioblastoma multiforme
31333911124300000LossGlioblastoma multiforme
41334011124300000LossGlioblastoma multiforme
51334111124300000LossGlioblastoma multiforme
6133591112600000GainGlioblastoma multiforme
7133651116100000GainGlioblastoma multiforme
8137501127800000LossGlioblastoma multiforme
9137611128000000DeletionGlioblastoma multiforme
10137631128000000GainGlioblastoma multiforme
11137751139600000LossGlioblastoma multiforme
12137921151300000LossGlioblastoma multiforme
1313822117200000DeletionMTHFRGlioblastoma multiforme
14143141107000000111600000GainGlioblastoma multiforme
15144141107915304108309068amplificationVAV3Glioblastoma multiforme
16146091109636509109651136FusionMYBPHLGlioblastoma multiforme
17154031115061059115084034FusionCSDE1Glioblastoma multiforme
18164351124300000247249719GainGlioblastoma multiforme
19164361124300000247249719GainGlioblastoma multiforme
20164371124300000247249719GainGlioblastoma multiforme
21164441124300000247249719LossGlioblastoma multiforme
22166831130300000212100000GainATP2B4Glioblastoma multiforme
23190081148161834148166860Copy numberSF3B4Glioblastoma multiforme
24197911151370387155734861GainCLK2Glioblastoma multiforme
25206001153272923153289968FusionDCST1Glioblastoma multiforme
26206121153300000154800000GainRAB25Glioblastoma multiforme
27211141156847119156923130Copy numberSPTA1Glioblastoma multiforme
282204111645083116482564Copy numberEPHA2Glioblastoma multiforme
29236821172900000185800000GainGlioblastoma multiforme
30242881178190530178346919FusionCEP350Glioblastoma multiforme
31254281189000000197500000GainGlioblastoma multiforme
32255671191357783191486465FusionCDC73Glioblastoma multiforme
33261371197500000205300000AmplificationLRRN5Glioblastoma multiforme
34261381197500000205300000AmplificationMDM4Glioblastoma multiforme
35261391197500000205300000AmplificationMDM4Glioblastoma multiforme
36261421197500000205300000AmplificationNFASCGlioblastoma multiforme
37261461197500000205300000AmplificationlicationHDMXGlioblastoma multiforme
38264741200429740200554958TruncationLGR6Glioblastoma multiforme
39265151200858000202110000Copy numberMDM4Glioblastoma multiforme
40266601201942811203355851AmplificationMDM4Glioblastoma multiforme
41285541223214607229308654GainARF1Glioblastoma multiforme
42285551223214607229308654GainWNT3AGlioblastoma multiforme
43296261233890968234060340FusionLYSTGlioblastoma multiforme
44302891241700000247249719AmplificationAKT3Glioblastoma multiforme
4530407124298342447886FusionPANK4Glioblastoma multiforme
4631747130500000171200000GainGlioblastoma multiforme
4732775139284173978407DeletionGlioblastoma multiforme
4832899140284046333694DeletionAJAP1Glioblastoma multiforme
4932900140284046333694DeletionCHD5Glioblastoma multiforme
50338761495224820897624DeletionCDC42Glioblastoma multiforme

Expression for genes affiliated with Glioblastoma Multiforme

About this section
Search GEO for disease gene expression data for Glioblastoma Multiforme.

Pathways for genes affiliated with Glioblastoma Multiforme

About this section

Pathways related to Glioblastoma Multiforme according to GeneCards Suite gene sharing:

(show top 50)    (show all 161)
idSuper pathwaysScoreTop Affiliating Genes
19.8CDKN2A, MDM2, MYC, TP53
29.6AKT1, CDK2, CDK4, MTOR, MYC
39.6AKT1, EGF, EGFR, MTOR, MYC
49.6CDK2, CDK4, MDM2, MYC, TP53
5
Show member pathways
9.6AKT1, CDK2, GSK3B, MDM2, TP53
69.6EGF, EGFR, MYC, PDGFRA, PDGFRB
79.6CDK4, CDK6, CDKN2A, MDM2, TP53
89.5CDKN2A, GSK3B, MDM2, MTOR, PTEN, TP53
9
Show member pathways
9.5AKT1, CDK2, CDK4, EGF, EGFR, GPNMB
109.4AKT1, AKT3, EGF, EGFR, GSK3B, TP53
11
Show member pathways
9.4AKT1, AKT3, CDK2, CDKN2A, MDM2, MTOR
129.4CDK2, CDK4, CDK6, MDM2, MYC, TP53
13
Show member pathways
9.4AKT1, AKT3, CDK2, EGF, EGFR, MDM2
149.4AKT1, AKT3, EGFR, MDM2, MTOR, MYC
159.4AKT1, AKT3, EGF, EGFR, MDM2, MTOR
16
Show member pathways
9.3AKT1, AKT3, EGF, EGFR, MTOR, PDGFRA
179.3AKT1, AKT3, GSK3B, MDM2, MTOR, MYC
189.3AKT1, AKT3, CDK2, GSK3B, MDM2, MYC
199.2CDK4, CDKN2A, EGF, EGFR, MDM2, MYC
20
Show member pathways
9.2AKT1, CDK2, CDK4, MDM2, MTOR, MYC
21
Show member pathways
9.2AKT1, AKT3, GSK3B, MDM2, MTOR, MYC
22
Show member pathways
9.2AKT1, AKT3, CDK2, CDK4, GSK3B, MDM2
23
Show member pathways
9.2AKT1, AKT3, EGF, EGFR, MYC, PDGFRA
24
Show member pathways
9.1AKT1, AKT3, EGF, EGFR, GSK3B, MDM2
259.1AKT1, AKT3, CDK2, CDK4, CDK6, MYC
269.1AKT1, AKT3, EGF, EGFR, MYC, PDGFRA
27
Show member pathways
9.1AKT1, AKT3, CDKN2A, GSK3B, MDM2, MYC
28
Show member pathways
9.1CDK2, CDK4, CDK6, CDKN2A, MDM2, MYC
299.1AKT1, CDK2, CDK4, EGFR, MDM2, MTOR
30
Show member pathways
9.1AKT1, AKT3, EGFR, GSK3B, MTOR, PDGFRA
319.0AKT1, AKT3, CDK2, CDK4, CDK6, GSK3B
32
Show member pathways
9.0AKT1, AKT3, EGFR, GSK3B, MDM2, MTOR
339.0CDK2, CDK4, CDK6, CDKN2A, GSK3B, MDM2
34
Show member pathways
8.9AKT1, AKT3, CDK2, CDK4, CDKN2A, MDM2
358.9AKT1, AKT3, EGFR, IDH1, MTOR, MYC
36
Show member pathways
8.9AKT1, AKT3, EGF, EGFR, GSK3B, MDM2
37
Show member pathways
8.9AKT1, AKT3, EGF, EGFR, MDM2, MTOR
38
Show member pathways
8.9AKT1, AKT3, CDK6, EGF, EGFR, GSK3B
398.9AKT1, AKT3, CDK4, CDKN2A, GSK3B, MYC
408.8AKT1, CDK2, CDK4, EGF, EGFR, MDM2
418.8CDK6, CDKN2A, EGFR, MDM2, MTOR, MYC
42
Show member pathways
8.8AKT1, AKT3, EGF, EGFR, GSK3B, MDM2
43
Show member pathways
8.7AKT1, AKT3, CDK4, CDK6, CDKN2A, EGF
44
Show member pathways
8.6AKT1, AKT3, EGF, EGFR, GSK3B, MDM2
45
Show member pathways
8.3AKT1, AKT3, CDK2, CDK4, EGFR, GSK3B
46
Show member pathways
7.9AKT1, AKT3, CDK2, CDK4, CDK6, CDKN2A
477.9AKT1, AKT3, CDK2, CDK4, CDK6, EGF
487.7AKT1, AKT3, CDK2, CDK4, CDK6, CDKN2A
49
Show member pathways
7.7AKT1, AKT3, CDK2, CDK4, CDK6, CDKN2A
507.6AKT1, AKT3, CDK2, CDK4, CDK6, CDKN2A

GO Terms for genes affiliated with Glioblastoma Multiforme

About this section

Cellular components related to Glioblastoma Multiforme according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1cyclin-dependent protein kinase holoenzyme complexGO:000030710.6CDK2, CDK4, CDK6
2protein complexGO:004323410.1AKT1, MDM2, MYC, PDGFRA, TP53
3cytosolGO:00058298.6AKT1, CDK2, CDK4, CDK6, CDKN2A, GSK3B
4nucleoplasmGO:00056548.4AKT1, AKT3, CDK2, CDK4, CDK6, MDM2
5nucleusGO:00056347.9AKT1, CDK2, CDK4, CDK6, CDKN2A, EGFR
6cytoplasmGO:00057377.7AKT1, AKT3, CDK2, CDK6, CDKN2A, DMBT1

Biological processes related to Glioblastoma Multiforme according to GeneCards Suite gene sharing:

(show top 50)    (show all 68)
idNameGO IDScoreTop Affiliating Genes
1metanephric glomerular capillary formationGO:007227710.9PDGFRA, PDGFRB
2positive regulation of cell proliferation by VEGF-activated platelet derived growth factor receptor signaling pathwayGO:003809110.8PDGFRA, PDGFRB
3negative regulation of NFAT protein import into nucleusGO:005153410.8GSK3B, MTOR
4response to UV-AGO:007014110.8AKT1, EGFR
5cellular response to decreased oxygen levelsGO:003629410.8AKT1, PTEN
6response to insulin-like growth factor stimulusGO:199041810.8AKT1, GSK3B
7positive regulation of mitochondrial membrane potentialGO:001091810.7GSK3B, MYC
8negative regulation of monocyte differentiationGO:004565610.7CDK6, MYC
9cellular response to phorbol 13-acetate 12-myristateGO:190462810.7CDK6, MYC
10re-entry into mitotic cell cycleGO:000032010.7GSK3B, MYC
11platelet-derived growth factor receptor signaling pathwayGO:004800810.6PDGFRA, PDGFRB, PTEN
12peptidyl-threonine phosphorylationGO:001810710.6AKT1, GSK3B, MTOR
13negative regulation of cell sizeGO:004579210.6AKT1, MTOR, PTEN
14positive regulation of cell cycleGO:004578710.5CDK4, MDM2, MYC
15ERBB2 signaling pathwayGO:003812810.5AKT1, EGF, EGFR
16cellular response to epidermal growth factor stimulusGO:007136410.5AKT1, EGFR, MYC
17positive regulation of protein export from nucleusGO:004682710.5GSK3B, MDM2, TP53
18positive regulation of nitric oxide biosynthetic processGO:004542910.5AKT1, EGFR, MTOR
19phosphatidylinositol phosphorylationGO:004685410.4EGF, EGFR, PDGFRA, PDGFRB
20regulation of cell motilityGO:200014510.3CDK6, EGF, EGFR
21regulation of signal transduction by p53 class mediatorGO:190179610.3AKT1, CDK2, MDM2, TP53
22cellular response to organic cyclic compoundGO:007140710.3AKT1, MDM2, MGMT, MYC
23peptidyl-tyrosine phosphorylationGO:001810810.3EGF, EGFR, PDGFRA, PDGFRB
24positive regulation of DNA biosynthetic processGO:200057310.3GSK3B, MYC, PDGFRB
25regulation of phosphatidylinositol 3-kinase signalingGO:001406610.3AKT1, EGF, EGFR, PDGFRA, PDGFRB
26G1/S transition of mitotic cell cycleGO:000008210.2CDK2, CDK4, CDK6, CDKN2A
27regulation of neuron projection developmentGO:001097510.2AKT1, GSK3B, PTEN
28canonical Wnt signaling pathwayGO:006007010.1EGF, GSK3B, MYC, PTEN
29positive regulation of smooth muscle cell proliferationGO:004866110.1EGFR, GSK3B, MTOR, MYC, PDGFRB
30response to organic cyclic compoundGO:001407010.1EGFR, IDH1, MGMT, PDGFRB, PTEN
31cell cycle arrestGO:000705010.1CDK6, CDKN2A, MTOR, MYC, TP53
32regulation of gene expressionGO:001046810.0CDK4, CDK6, MDM2, MYC
33peptidyl-serine phosphorylationGO:001810510.0AKT1, AKT3, CDK2, GSK3B, MTOR
34cellular response to hypoxiaGO:007145610.0AKT1, MDM2, MTOR, PTEN, TP53
35MAPK cascadeGO:000016510.0EGF, EGFR, MYC, PDGFRA, PDGFRB
36positive regulation of apoptotic processGO:004306510.0AKT1, CDK4, PDGFRB, PTEN, TP53
37phosphatidylinositol-mediated signalingGO:004801510.0AKT1, EGF, EGFR, MTOR, PDGFRA, PDGFRB
38protein autophosphorylationGO:004677710.0AKT1, EGFR, GSK3B, MTOR, PDGFRA, PDGFRB
39cell proliferationGO:00082839.9AKT1, EGFR, MYC, PTEN, TP53
40positive regulation of ERK1 and ERK2 cascadeGO:00703749.9EGFR, PDGFRA, PDGFRB, PTEN
41positive regulation of fibroblast proliferationGO:00481469.9CDK4, CDK6, EGFR, MYC, PDGFRA, PDGFRB
42wound healingGO:00420609.9EGFR, MTOR, PDGFRA, PDGFRB
43intracellular signal transductionGO:00355569.8AKT1, AKT3, EGFR, GSK3B, PDGFRB
44response to toxic substanceGO:00096369.7CDK2, CDK4, MDM2, MGMT, PDGFRB
45response to estradiolGO:00323559.7CDK2, EGFR, GSK3B, MYC, PDGFRB, PTEN
46protein phosphorylationGO:00064689.6AKT1, AKT3, CDK2, CDK4, CDK6, GSK3B
47response to ethanolGO:00454719.6CDK2, MGMT, MYC, PTEN
48response to drugGO:00424939.2CDK2, CDK4, GSK3B, MDM2, MGMT, MYC
49negative regulation of apoptotic processGO:00430669.2AKT1, EGFR, GSK3B, MDM2, MGMT, MYC
50positive regulation of cell proliferationGO:00082848.8CDK2, CDK4, EGF, EGFR, MDM2, MYC

Molecular functions related to Glioblastoma Multiforme according to GeneCards Suite gene sharing:

(show all 14)
idNameGO IDScoreTop Affiliating Genes
1vascular endothelial growth factor bindingGO:003808510.8PDGFRA, PDGFRB
2nitric-oxide synthase regulator activityGO:003023510.8AKT1, EGFR
3platelet-derived growth factor receptor bindingGO:000516110.7PDGFRA, PDGFRB, PTEN
4cyclin-dependent protein serine/threonine kinase activityGO:000469310.5CDK2, CDK4, CDK6
5cyclin bindingGO:003033210.5CDK2, CDK4, CDK6
6p53 bindingGO:000203910.5GSK3B, MDM2, TP53
7phosphatidylinositol-4,5-bisphosphate 3-kinase activityGO:004693410.4EGF, EGFR, PDGFRA, PDGFRB
8Ras guanyl-nucleotide exchange factor activityGO:000508810.2EGF, EGFR, PDGFRA, PDGFRB
9protein kinase activityGO:00046729.9AKT1, AKT3, CDK2, CDK4, GSK3B, MTOR
10protein serine/threonine kinase activityGO:00046749.8AKT1, AKT3, CDK2, GSK3B, MTOR
11kinase activityGO:00163019.8AKT1, CDK2, CDK4, CDK6, EGFR, GSK3B
12enzyme bindingGO:00198999.7AKT1, EGFR, MDM2, PTEN, TP53
13protein kinase bindingGO:00199018.8AKT1, CDKN2A, EGFR, GSK3B, MTOR, PDGFRB
14ATP bindingGO:00055248.6AKT1, AKT3, CDK2, CDK4, CDK6, EGFR

Sources for Glioblastoma Multiforme

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
25GTR
26HGMD
27HMDB
28ICD10
29ICD10 via Orphanet
30ICD9CM
31IUPHAR
32KEGG
35MedGen
37MeSH
38MESH via Orphanet
39MGI
42NCI
43NCIt
44NDF-RT
47NINDS
48Novoseek
50OMIM
51OMIM via Orphanet
55PubMed
56QIAGEN
61SNOMED-CT via Orphanet
65Tumor Gene Family of Databases
66UMLS
67UMLS via Orphanet